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1 Introduction 
In 1928, Alexander Fleming discovered the first antibiotic – penicillin – that was 
subsequently developed for clinical use (Fleming, 1929). The effective treatment of 
previously deadly infectious diseases revolutionised medicine, and contributed to 
increasing human life expectancy.  
Since that time, numerous natural and synthetic antimicrobial substances have been 
identified. However, the development and clinical use of each new antibiotic class was 
followed by emergence of resistant bacteria. Today, the therapeutic options for multidrug 
resistant pathogens are limited, and in the last decade only two new antibiotic classes 
entered the market. Consequently, there is an urgent need to discover and develop novel 
anti-infective agents to combat pathogenic bacteria (Brotz-Oesterhelt and Sass, 2010; 
Davies and Davies, 2010).  
Host defence peptides, which are produced by almost all eukaryotic organisms, are 
considered as a promising source of potential antibiotics since they combine direct 
antibacterial activities with modulation of immune response. Moreover, they are also 
active against those bacteria resistant to conventional antibiotics and show only modest 
resistance development under in vitro selection pressure (Hancock and Sahl, 2006; 
Yeung et al., 2011).  
1.1 Host Defence Peptides 
Multicellular organisms defend themselves against invading pathogens by producing a 
variety of antimicrobial peptides referred to as host defence peptides (HDPs). These 
peptides are an essential component of the ancient, non-specific innate immune system 
that represents a first line of host defence. Depending on the organism and tissue type, 
HDP expression can be constitutive or induced in response to infection and provide either 
a systemic or a local protection of the host. 
HDPs display direct antimicrobial activity against a broad range of microorganisms, 
including bacteria, fungi and even certain protozoa and enveloped viruses. The most 
potent peptides kill at low micromolar concentrations and some also exert activity against 
multidrug resistant microbes. In addition to their function as endogenous antibiotics, they 
exhibit various immunomodulatory activities (section 1.4).  
Generally, HDPs are gene-encoded peptides and derive from larger precursors by 
proteolytic processing. They are short (12 to 50 amino acids), cationic (net charge ranging 
from +2 to +11) and are able to adopt an amphipathic structure (often in contact with 
membranes) in which hydrophobic and cationic amino acid residues are clustered into 
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distinct domains (Ganz and Lehrer, 1998; Hancock and Lehrer, 1998; Jenssen et al., 
2006; Zasloff, 2002). 
Over the past decades, more than one thousand of these peptides from plants, fungi, 
invertebrates and vertebrates have been identified, indicating the abundance of HDPs. 
Their sequences are compiled in three antimicrobial peptide databases 
(http://aps.unmc.edu/AP/main.html; http://www.bbcm.univ.trieste.it/~tossi/pag1.htm; 
http://phytamp.pfba-lab-tun.org/main.php). Despite a high degree of sequence variation, 
HDPs have been classified into four groups according to their secondary structure, amino 
acid composition and number of disulphide bonds:  
 
(i) linear α-helical peptides that do not contain cysteine residues, e.g. LL-37 
(human), magainin (frog; Figure 1);  
(ii) cysteine-free, extended helical peptides with a predominance of one or two 
amino acids, such as tryptophan-rich indolicidin (cow; Figure 1) or proline-
rich PR-39 (pig); 
(iii)  peptides with a loop structure and two disulphide-bridged cysteines; 
representatives are bactenecin (cow) and thanatin (insect; Figure 1); 
(iv) peptides containing β-sheet elements stabilised by two to four 
intramolecular disulphide bonds, e.g. hBD2 (human; Figure 1).  
 
The latter group includes defensins, a peptide family that was first discovered in mammals 
and subsequently found in invertebrates, plants and fungi (Hancock, 1997; Hancock and 
Diamond, 2000). 
 
 
 
Figure 1 Structures of host defence peptides (modified according to Jenssen et al., 2006). 
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1.2 Defensins 
Members of the defensin family can be found in three eukaryotic kingdoms – in fungi, 
plants and both invertebrate and vertebrate animals.  
Vertebrate defensins can be subdivided into three families, α-, β- and θ-defensins, based 
on precursor and gene structure as well as spacing and pairing of their six conserved 
cysteine residues. Both α- and β-defensins are composed of a triple-stranded antiparallel 
β-sheet structure stabilised by three disulphide bridges (Figure 2). Alpha-defensins 
(disulphide pairing C1-C6, C2-C4, C3-C5) are present in high (up to millimolar) 
concentrations in the granules of neutrophils and small intestinal Paneth cells, whereas β-
defensins (disulphide pairing C1-C5, C2-C4, C3-C6) are mainly expressed in epithelial 
tissues. 
To date, four human neutrophilic α-defensins (HNP1-4), two human enteric α-defensins 
(HD5, HD6) and four human epithelial β-defensins (hBD1-4) have been characterised that 
differ substantially in their potency and activity spectra (Gram-positive and Gram-negative 
bacteria, fungi, viruses) (Ganz, 2003; Schneider et al., 2005). Interestingly, human β-
defensin 1 (hBD1) becomes a potent antimicrobial peptide only after reduction of its 
disulphide bonds, then acting against the yeast Candida albicans and anaerobic Gram-
positive commensals of the gut (Schroeder et al., 2011).  
However, bioinformatic approaches revealed that the human genome encodes more than 
30 β-defensin genes in five chromosomal regions (Schutte et al., 2002; Yamaguchi et al., 
2002). The expression of many of these genes has been confirmed on mRNA level; 
several are specifically expressed in the testis and epididymis (Pazgier et al., 2006; 
Rodriguez-Jimenez et al., 2003; Yamaguchi et al., 2002), suggesting an involvement of β-
defensins in sperm maturation (Zhou et al., 2004). In addition to defensins, humans 
synthesise the α-helical cathelicidin LL-37. Cathelicidins comprise structurally diverse 
HDPs whose precursors contain a conserved N-terminal cathelin domain and a C-terminal 
antimicrobial domain (Durr et al., 2006).  
Theta-defensins have been isolated so far from the neutrophils and monocytes of several 
species of Old World monkeys and arose from a pre-existing α-defensin. Their peptide 
backbone is cyclised by ligation of two identical or similar nonapeptides and the resulting 
peptide ring is stabilised by six disulphide-bridged cysteines (disulphide pairing C1-C6, 
C2-C5, C3-C4; Figure 2) (Tang et al., 1999; Tran et al., 2002). Noteworthy, there are six 
θ-defensin genes present in the human genome, but a premature stop codon in the signal 
sequence aborts their translation, thus causing a higher susceptibility of humans towards 
HIV-1 infections (Nguyen et al., 2003). 
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Invertebrate defensins have been found in the hemolymph (plasma and hemocytes) and 
certain epithelial cells of arthropods (e.g. insects) and mollusks. Functionally, antibacterial 
(primarily active against Gram-positive bacteria) and antifungal peptides can be 
distinguished which differ from vertebrate defensins by their disulphide bridging patterns 
(C1-C4, C2-C5, C3-C6 for peptides containing six cysteines). The core structure of 
invertebrate defensins is composed of an α-helical domain linked to a two-stranded 
antiparallel β-sheet with three or four disulphide bonds forming the so-called cysteine-
stabilised α-helix β-sheet (CSαβ) motif (Figure 2). Some antifungal peptides like 
drosomycin from Drosophila melanogaster contain an additional short N-terminal β-strand 
presenting a βαββ-scaffold that is similar to that of antifungal plant defensins (Figure 2) 
(Bulet et al., 2004; Thomma et al., 2002). Meanwhile, peptides of another defensin family 
referred to as “big defensins” have been isolated from invertebrates (Gerdol et al., 2011; 
Rosa et al., 2011; Saito et al., 1995; Teng et al., 2012; Zhao et al., 2007). They consist of 
79-94 amino acids that form two distinct structural and functional domains. The 
hydrophobic N-terminus exhibits selective activity against Gram-positive bacteria, while 
the hydrophilic C-terminus displays Gram-negative activity. Interestingly, the C-terminal 
region adopts the typical fold of β-defensins with identical disulphide arrays (C1-C5, C2-
C4, C3-C6; Figure 2), suggesting that β-defensins emerged from an ancestral big 
defensin (Zhu and Gao, 2012).  
Defensins with a high degree of sequence and structural similarity to invertebrate 
defensins have been identified in several fungi (Mygind et al., 2005; Zhu, 2008). For 
example, plectasin isolated from the saprophytic ascomycete Pseudoplectania nigrella is 
characterised by a CSαβ motif (disulphide pairing C1-C4, C2-C5, C3-C6; Figure 2) and 
displays potent antibacterial activity (Mygind et al., 2005). 
All plant defensins known so far are characterised by four disulphide bridges and share 
the same cysteine pairing pattern (C1-C8, C2-C5, C3-C6, C4-C7; Figure 2). They are 
mainly active against fungi, including plant and human pathogens (Tavares et al., 2008; 
Thevissen et al., 2007). In past years, increasing evidence for other biological activities 
has been gathered such as inhibition of α-amylase activity and protein synthesis, antiviral 
and antitumour activity, inhibition of plant root growth, blocking of ion channels and 
mediation of zinc tolerance in plants (Aerts et al., 2008; Allen et al., 2008; Lin et al., 2009; 
Mirouze et al., 2006; Spelbrink et al., 2004; Wong and Ng, 2005). 
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Figure 2 Sequences and 3D structures of selected defensins. Residues with a positive charge are marked in red, negatively charged residues are marked in 
blue. The 3D structure of RTD-1 was taken from Trabi et al., 2009; all other 3D structures were obtained using Swiss Model 
(www.swissmodel.expasy.org). 
 Sequence 3D structure Defensin  Activity spectrum 
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It has been postulated that all defensins evolved from a single precursor, based on (i) 
sequence and structural similarity of plant and insect defensins as well as fungal and 
antibacterial invertebrate defensins, (ii) similar mode of action of plant and insect 
defensins (section 1.3) and (iii) inter-functionality of defensins from different kingdoms 
(Thevissen et al., 2004; Zhu and Gao, 2012). In this respect, overexpression of insect 
(Langen et al., 2006) or mammalian defensins (Aerts et al., 2007) in plants resulted in 
increased plant resistance to fungal diseases, comparable to that obtained by 
overexpression of plant defensins. Vice versa, intravenous injection of plant defensins into 
C. albicans infected mice resulted in a significant reduction of the fungal burden in the 
kidneys of the infected mice at least as efficiently as the standard drug fluconazole 
(Tavares et al., 2008). In line with these observations, Yount and Yeaman (2004) 
identified a conserved three-dimensional structural motif in disulphide-containing host 
defence peptides from virtually all organisms, the so-called γ-core motif (Figure 3).  
 
 
 
Figure 3 The common ancestor hypothesis of disulphide-stabilised host defence effector molecules. 
The γ-core structural motiv conferring antimicrobial activity has been conserved during 
evolution and can be traced back to prokaryotic origin (Yeaman and Yount, 2007). 
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This motif arises from the bidirectional orientation of a specific amino acid sequence and 
is composed of two antiparallel β-sheets with an interposed short turn region. Indeed, this 
motif can also be found in other cysteine-stabilised host defence effector molecules with 
antimicrobial activity like venoms, toxins or microbicidal chemokines. Thus, it is proposed 
that disulphide-containing HDPs emerged from a common ancestral peptide that can be 
traced back to prokaryotic origin (Figure 3) (Yeaman and Yount, 2007).  
Consistent with this hypothesis, two defensin-like peptides (DLP) were recently identified 
in the myxobacteria Anaeromyxobacter dehalogenans and Stigmatella aurantiaca. 
Despite the lack of two cysteine residues, the A. dehalogenans DLP exhibits the typical 
CSαβ fold of fungal, invertebrate and plant defensins and displays activity against the 
malaria parasite Plasmodium falciparum (Gao et al., 2009; Zhu, 2007). 
1.3 Antimicrobial mode of action of HDPs 
Almost all HDPs are cationic and amphipathic. Hence, it has been frequently 
demonstrated, using model membranes and unilamellar vesicles of various lipid 
compositions, that HDPs interact with negatively charged components of the microbial 
surface and subsequently disrupt membrane barrier function via pore-formation or 
unspecific membrane permeabilisation (Gazit et al., 1995; Henzler-Wildman et al., 2004; 
Yang et al., 1998; Yang et al., 2001). Numerous reports on biophysical behaviour of 
synthetic and natural peptides in lipid bilayers were published and different models have 
been elaborated to describe the membrane-peptide interaction. The best studied peptides 
among HDPs are linear peptides that are unstructured in solution and adopt an α-helical 
conformation in the presence of membranes.  
In this context, it was reasoned that positively charged cationic peptides are 
electrostatically attracted to negatively charged phospholipids which are typically present 
in the outer leaflet of microbial membranes. With increasing peptide concentration the 
peptide molecules insert into the bilayer either forming transmembrane pores or disrupting 
the membrane in a detergent-like manner (Brogden, 2005; Zasloff, 2002). For example, 
the formation of “toroidal pores” was demonstrated for magainin 2 (Yang et al., 1998) and 
LL-37 (Henzler-Wildman et al., 2004), whereas the induction of “barrel-stave” pores 
seems unique for the non-ribosomal peptide antibiotic alamethicin (Yang et al., 2001). 
Alternatively, peptides such as cecropins accumulate parallel to the membrane surface 
and at sufficient high concentration cause disintegration of the lipid bilayer (“carpet 
model”) (Gazit et al., 1995; Zasloff, 2002). In all model systems, membrane 
permeabilisation depends on the lipid composition (chain length and charge of 
phospholipids). The interaction of peptides is strongly reduced by zwitterionic 
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phospholipids or cholesterol, both prominent constituents of eukaryotic cell membranes - 
a feature that might explain the reduced toxicity towards host cells.  
Hence, in the past, discussions on the mode of microbicidal action of HDPs mainly 
focused on the lipid bilayer as a target, whereas membrane proteins making up 50% or 
more of microbial membranes were hardly considered. While the relevance of the lipid 
interactions for the attraction of HDPs to the membrane interface can hardly be 
questioned, the relevance for the actual killing process may be overestimated. There is 
increasing evidence that some HDPs enter the cytoplasm without disrupting the 
membrane bilayer; once inside the cell, they may interfere with nucleic acid and/or protein 
synthesis (Boman et al., 1993; Lehrer et al., 1989; Park et al., 1998; Patrzykat et al., 2002; 
Subbalakshmi and Sitaram, 1998). Moreover, HDPs have to cross barriers such as cell 
wall peptidoglycan or the outer membrane of Gram-negative bacteria to interact with the 
cytoplasmic membrane. For Gram-negative bacteria a translocation mechanism termed 
“self-promoted uptake” has been described. Thereby, the peptides first bind to the 
lipopolysaccharides (LPS) of the outer membrane and subsequently cause displacement 
of divalent cations (Mg2+, Ca2+) that bridge and neutralise LPS. Thus, destabilised outer 
membrane areas are formed through which peptides can translocate (Hancock, 1997).  
Recently, it has become evident that the fungal defensin plectasin (Schneider et al., 
2010), the α-defensin human neutrophil peptide 1 (HNP-1) (de Leeuw et al., 2010) and the 
human β-defensin 3 (hBD3) (Sass et al., 2010) specifically inhibit bacterial cell wall 
biosynthesis by targeting lipid II (Figure 27). Plectasin exhibits potent activity against 
several Gram-positive bacteria. It does not compromise membrane integrity at all, since 
no impact on membrane potential and on intracellular K+ contents could be observed with 
cells exposed to plectasin concentrations in the MIC range. Instead, in vitro and in vivo 
experiments demonstrated that plectasin forms a stoichiometric complex with the cell wall 
precursor lipid II in a 1:1 molar ratio, thus making it unavailable for the interaction with cell 
wall biosynthetic enzymes. NMR-based modelling of the plectasin-lipid II complex 
indicated that the defensin interacts with the pyrophosphate moiety of lipid II via hydrogen 
bonding, whereas the hydrophobic part of the peptide is located on the membrane 
surface. Additionally, a salt bridge between the N-terminus (H18) and the D-glutamic acid 
in position 2 of the stem peptide is crucial for binding (Figure 4) (Schneider et al., 2010). 
The killing of S. aureus by hBD3 is the result of pleiotropic effects. Beside lipid II 
sequestration, the peptide seems to have more generalised effects on membrane bound 
processes such as the electron transport chain (Sass et al., 2008; Sass et al., 2010). De 
Leeuw et al. (2010) proposed that the antimicrobial action of HNP-1 is also based on  
lipid II binding as the ability of the peptide to kill S. aureus is strongly reduced in cells with 
altered lipid II levels. Moreover, they showed that the affinity towards lipid II is significantly 
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higher for the natural peptide than for a synthetic peptide composed entirely of D-amino 
acids. 
 
 
 
Figure 4 A: NMR-based modelling of the plectasin-lipid II complex. B: The fungal defensin interacts 
with the pyrophosphate moiety of lipid II by forming four hydrogen bonds (involving residues 
F2, G3, C4 and C37). Moreover, the D-glutamate of lipid II forms a salt bridge with the N-
terminus and the H18 side-chain of plectasin (Schneider et al., 2010). 
 
Additional antibacterial effects could be observed for LL-37 and indolicidin. At 
subinhibitory concentrations, both peptides prevent potently the biofilm formation of 
Pseudomonas aeruginosa and even induce the dissolution of existing biofilms. It has been 
shown that LL-37 acts in three ways: it reduces the attachment of cells to the surface, 
stimulates the surface motility of cells and affects the two major quorum sensing systems 
– Las and RhI – resulting in downregulation of essential biofilm-related genes (Overhage 
et al., 2008). 
 
The antifungal action of plant and insect defensins is based on interaction with particular 
sphingolipids in membranes and cell walls of susceptible fungi. Sphingolipids are an 
important structural component of eukaryotic membranes and are also recognised as 
secondary messenger molecules regulating the equilibrium between cell death and cell 
growth processes (Thevissen et al., 2006). The interaction of the plant defensin Rs-AFP2 
(Raphanus sativus antifungal protein 2) with glucosylceramides (GlcCer) in the fungal 
membrane modulates cellular processes such as apoptosis, thereby leading to fungal cell 
death (Aerts et al., 2009; Thevissen et al., 2007). Moreover, it has been demonstrated that 
binding of Rs-AFP2 to GlcCer in the cell wall of C. albicans causes cell wall stress, septin 
mislocalisation and ceramide accumulation (Thevissen et al., 2012).  
The interaction with GlcCer has also been reported for Psd1 (from pea seeds) (de 
Medeiros et al., 2010), Sd5 (from Saccharum officinarum) (De-Paula et al., 2008), MsDef1 
(from Medicago sativa) (Ramamoorthy et al., 2007) and the insect defensin heliomicin 
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(from Heliothis virescens) (Thevissen et al., 2004). Other plant defensins such as 
DmAMP1 (from Dahlia merckii) bind specifically to inositol phosphoryl-containing 
sphingolipids leading to membrane permeabilisation and ion efflux (Thevissen et al., 2003; 
Thevissen et al., 1996).  
 
Some HDPs also exhibit antiviral activity by targeting the viral envelope directly, the viral 
adsorption and entry into the cell or the intracellular viral life cycle (Ding et al., 2009; 
Jenssen et al., 2006). Rhesus macaque θ-defensins (RTDs) and retrocyclins (synthetic θ-
defensins encoded by human pseudogenes) inhibit HIV-1 attachment and entry by binding 
specifically to both the viral envelope glycoproteins gp120 or gp41 and the host cell 
receptor CD4 (Cole et al., 2002; Gallo et al., 2006; Munk et al., 2003; Seidel et al., 2010; 
Wang et al., 2004). The α-defensins HNP1-3 seem to have a direct effect on several 
enveloped viruses such as herpes simplex virus type 1 and 2 or influenza A virus, as the 
virions lose their ability to infect target cells after incubation with the peptides (Daher et al., 
1986). Moreover, HNP1-3 inhibit multiple steps of the HIV life cycle, e.g. nuclear import 
and HIV replication (Chang et al., 2005; Furci et al., 2007; Mackewicz et al., 2003; Seidel 
et al., 2010; Wang et al., 2004). Antiviral properties have also been reported for β-
defensins. For example, hBD2 does not only inactivate HIV particles directly, but also 
inhibits HIV replication (Seidel et al., 2010; Sun et al., 2005). 
1.4 Immunomodulatory functions of HDPs 
Research during the last years has demonstrated that HDPs do not only have direct 
antimicrobial activities, but also display a diverse range of immunomodulatory functions 
(Figure 5). As the antibacterial properties of several HDPs are strongly antagonised under 
physiological salt concentrations or serum components, it has been proposed that the 
immunomodulatory activities of some of these peptides may be more important to mediate 
bacterial clearance in vivo.  
Mammalian HPDs are expressed either constitutively or are inducible in various cell types 
such as neutrophils, monocytes/macrophages and epitheliaI cells. The expression of 
human β-defensins can be triggered by conserved bacterial structures (e.g. LPS) via Toll-
like receptors (TLR) or by proinflammatory stimuli (e.g. TNF-α, IL-1β or IFN-γ). In contrast, 
α-defensins are expressed constitutively in the bone marrow and intestinal Paneth cells, 
but their secretion can be stimulated, e.g. by bacterial antigens such as OmpA or flagellin 
(Hancock and Scott, 2000; Selsted and Ouellette, 2005).  
It has been revealed that HDPs can be chemotactic for various immune cells or they can 
induce the production and release of particular cytokines/chemokines, thereby recruiting 
effector cells to the site of infection (Chertov et al., 1996; Territo et al., 1989; Yang et al., 
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2000; Yang et al., 1999). For example, hBD1 and hBD2 are chemotactic for memory  
T cells and immature dendritic cells by binding directly to the chemokine receptor CCR6 
(Figure 5) (Yang et al., 1999), thus providing an important link between innate and 
adaptive immune response. HNP1-3 can attract monocytes, immature dendritic cells and 
CD4+ and CD8+ T cells (Territo et al., 1989; Yang et al., 2000). Moreover, they can induce 
the release of proinflammatory cytokines such as IFN-λ, IL-6 and IL-10 from T cells and  
TNF-α and IL-1β from monocytes (Froy, 2005; Lehrer and Ganz, 2002). The release of 
TNF-α and IFN-γ from macrophages stimulates in an autocrine loop the activity of 
phagocytic macrophages, and thereby enhances clearance of opsonised bacteria in vitro 
and in a murine model (Soehnlein et al., 2008). Additionally, several HDPs are involved in 
the production and release of histamine from mast cells (Niyonsaba et al., 2001). 
 
 
 
Figure 5 Immunomodulatory activities of vertebrate defensins (Lehrer, 2004).  
 
On the other hand, HDPs can dampen harmful proinflammatory immune responses. The 
release of bacterial products such as LPS of Gram-negative bacteria can result in 
excessive inflammatory responses which lead to sepsis or related syndromes. Many 
peptides can limit the production of sepsis-mediating proinflammatory cytokines in TLR-4-
stimulated macrophages (Scott et al., 2000; Semple et al., 2011), neutralise extracellular 
LPS (Mookherjee et al., 2007) and/or stimulate the expression of anti-inflammatory genes 
(Nijnik et al., 2009).  
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Further, HDPs are involved in wound healing. HBD2 and hBD3 are highly expressed in 
epidermal keratinocytes in response to injury or infection of the skin. They increase 
keratinocyte migration and proliferation through epidermal growth factor receptor 
signalling (Niyonsaba et al., 2007). HNP1-3 induce cell proliferation and wound closure as 
well as increased cell migration in the airway epithelia (Aarbiou et al., 2002; Aarbiou et al., 
2004).  
In addition, defensins can neutralise toxins secreted by bacterial pathogens, thereby 
inhibiting their cytocidal activity. It has been shown that HNP1-3 inhibit the function of 
lethal toxin from Bacillus anthracis in vitro and in vivo as well as of diphtheria toxin from 
Corynebacterium diphtheriae and P. aeruginosa endotoxin A (Kim et al., 2005; Kim et al., 
2006). 
The increasing knowledge about the immunomodulatory functions of HDPs led to the 
development of synthetic innate defence regulators (IDRs). IDRs are small, synthetic 
peptides derived from natural HDP templates which lack direct antimicrobial activity.  
IDR-1, whose sequence is based on bovine bactenecin, confers protection in a broad 
range of mice infection models, e.g. against MRSA, VRE and Salmonella. It selectively 
enhances immunity of the host by stimulating chemokine production by monocytes while 
suppressing potentially harmful excessive inflammatory responses (Scott et al., 2007).  
1.5 HDP expression and human disorders 
The gene copy number or the dysregulated expression of certain HDPs affects the 
pathogenesis of several infectious and inflammatory diseases, underlining the importance 
of these peptides in combating bacterial pathogens.  
Crohn´s disease (CD) is a chronic inflammatory bowel disease that most commonly 
affects the ileum of the small intestine and the colon. The disease is in part attributed to 
the colonising bacteria of the intestine that trigger mucosal inflammation. It has been 
demonstrated that patients with ileal CD have a reduced expression of the intestinal 
Paneth cell α-defensins HD5 and HD6, suggesting that α-defensins play a role in 
controlling the progress of CD pathogenesis. Consistently, changes in the intestinal 
microbiota of transgenic mice producing HD5 in intestinal Paneth cells have been 
observed (Wehkamp et al., 2005). The detailed analysis of the intestinal flora of HD5-
expressing mice and mice lacking Paneth cell α-defensins (due to a knockout of the 
processing enzyme MMP-7) clearly revealed α-defensin dependent alterations in the 
microbial composition, but not in the bacterial number. Thus, the deficiency of α-defensins 
in ileal CD may cause an imbalance of the microbial composition which in turn triggers 
infection and inflammation (Salzman et al., 2010). The lack of intestinal α-defensins has 
been linked to a diminished expression of the transcription factor Tcf-4 of the Wnt 
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signalling pathway which regulates differentiation of Paneth cells and α-defensin 
expression (Wehkamp et al., 2007).  
In contrast, colonic CD seems to be associated with a low copy number of β-defensin 
genes encoded in a cluster on chromosome 8 (Fahlgren et al., 2004; Wehkamp et al., 
2003). Fellermann et al. (2006) reported that a copy number of DEFB4 (encoding hBD2) 
less than four predispose to colonic CD. 
Another HDP deficiency that correlates with high susceptibility to bacterial infections is 
Morbus Kostmann. Patients with this syndrome suffer from severe and frequent 
periodontal infections due to a lack of LL-37 and HNP1-3 (Putsep et al., 2002). Similarly, 
patients with a specific granule deficiency lacking neutrophilic α-defensins have an 
enhanced susceptibility to bacterial infections (Ganz et al., 1988).  
Moreover, cystic fibrosis (CF) has been associated with a lack of antimicrobial activity of 
HDPs. This disorder is caused by a mutation in a chloride channel (cystic fibrosis 
transmembrane conductance regulator) regulating the chloride and sodium movement 
across epithelial membranes. CF is characterised by persistent colonisation of the airway 
epithelia, in particular by P. aeruginosa, inducing chronic infection and inflammation 
(Gadsby et al., 2006). It has been proposed that the elevated salt concentrations in the 
airway fluid of CF patients antagonise HDPs (LL-37 and β-defensins), thereby allowing 
microbial colonisation (Guggino, 2001; Smith et al., 1996). Other studies suggested that 
hBD2 and hBD3 are proteolytically degraded by the cysteine proteases cathepsin B, L 
and S present in bronchoalveolar lavage (Taggart et al., 2003), and that the reduced 
antibacterial activity of LL-37 is a result of direct interaction of the peptide with DNA and 
filamentous (F)-actin as well as released LPS found in CF sputum (Bucki et al., 2007). So 
far, it is unclear which of the described mechanisms plays a role in vivo or if they act in 
combination. 
Moreover, HDPs protect the skin from bacterial infections and altered HDP expression 
levels have been related to various skin disorders. For example, patients with the 
inflammatory skin disease psoriasis rarely develop skin infections due to elevated HDP 
expression (Harder et al., 2007). In contrast, it has been assumed that the impaired 
induction of HDPs in the skin of patients with atopic dermatitis (AD) contribute to 
colonisation and infection with S. aureus (de Jongh et al., 2005; Nomura et al., 2003; Ong 
et al., 2002). Meanwhile, a study demonstrated that the expression of several HDPs is 
significantly induced in lesional skin of AD patients in comparison to healthy controls 
(Harder et al., 2010). Thus, further analysis is needed to elucidate the role of HDPs in AD. 
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1.6 Resistance towards HDPs 
Despite the fact that HDPs are ancient molecules, they have retained their potent 
antimicrobial activity throughout evolution. However, some bacterial pathogens evolved 
mechanisms to reduce their susceptibility towards HDPs.  
One of these countermeasures is based on the covalent modification of anionic cell 
envelope molecules, thus decreasing their net negative charge and their attraction to 
HDPs. The bifunctional protein MprF (multiple peptide resistance factor) of S. aureus 
catalyses the modification of the phospholipid phosphatidylglycerol with L-lysine and its 
translocation to the outer leaflet of the cytoplasmic membrane (Ernst et al., 2009; Peschel 
et al., 2001). Moreover, the anionic properties of teichoic acids, which are either anchored 
to membrane phospholipids or connected to peptidoglycan, are partially neutralised by D-
alanylation. This reaction is catalysed by the products of the dltABCD operon (D-alanyl-
lipoteichoic acid) (Peschel et al., 1999). Homologues of both MprF and DltABCD can be 
found in many pathogens (Ernst and Peschel, 2011; Peschel et al., 1999).  
In S. aureus and S. epidermidis, the expression of mprF and dltABCD is controlled by the 
two-component regulatory system GraRS (glycopeptide resistance associated; or also 
known as ApsRS, antimicrobial peptide sensor). It has been proposed that the histidine 
kinase GraS/ApsS senses HDPs via a short extracellular loop with a high density of 
negative charges (Li et al., 2007a; Li et al., 2007b). Moreover, the ABC-transporter 
VraFG, encoded in the same operon as graRS, seems to be crucial for sensing of 
antimicrobial peptides (Falord et al., 2012). Consequently, mutations in one of the genes 
involved in HDP sensing or cell envelope modification significantly enhance the killing by 
cationic antimicrobial peptides (Kristian et al., 2003; Li et al., 2007a; Peschel et al., 1999; 
Sass and Bierbaum, 2009). 
The two-component regulatory system PhoPQ, found in many Gram-negative species, 
induces the transcription of genes promoting resistance to HDPs and other cationic 
antimicrobial peptides, bacterial survival within macrophages and virulence. For example, 
the incorporation of an additional fatty acid into the lipid A portion of LPS changes the 
hydrophobicity of the outer membrane and reduces its permeability. Moreover, PhoPQ 
can activate a second two-component regulatory system, PmrAB (polymyxin resistance) 
which regulates the addition of aminoarabinose or ethanolamine to lipid A, thereby 
lowering its net negative charge (Gunn, 2008; Richards et al., 2010).  
Recently, another mechanism has been described that reduces the affinity to lipid II-
targeting defensins. The GatD/MurT enzyme complex of several Gram-positive pathogens 
is responsible for the amidation of D-glutamic acid at position 2 of the lipid II stem peptide 
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(compare section 1.3). Antisense-mediated depletion of GatD/MurT significantly increases 
the susceptibility to the fungal defensin plectasin (Munch et al., 2012).  
Another strategy to escape killing by HDPs relies on the proteolytic degradation of the 
peptides. HDPs with an α-helical structure like LL-37 can be easily cleaved by proteases 
such as the metalloprotease ZapA from Proteus mirabilis (Belas et al., 2004), aureolysin 
from S. aureus (Sieprawska-Lupa et al., 2004) or the outer membrane protease PgtE from 
Salmonella enterica serovar Typhimurium (Guina et al., 2000). Some bacteria remove 
HDPs from their site of action by active efflux. The energy-dependent efflux pump MtrCDE 
(multiple transferable resistance) of Neisseria gonorrhoeae confers resistance to 
structurally diverse antimicrobial agents, including HDPs (Shafer et al., 1998).  
However, all these mechanisms described above do not lead to high-level resistance. 
Molecules such as lipid II, LTA or LPS are formed by multistep biosynthetic processes and 
cannot be easily replaced or even modified without major genetic events and 
rearrangements. For example, the lipid II isoprenoid anchor C55-P is also involved in the 
biosynthesis of other major cell envelope polymers, e.g. wall teichoic acid and capsules. 
Synthesis of C55-P-anchored molecules always starts with the transfer of a sugar moiety to 
the lipid carrier, forming a pyrophosphate linkage. Thus, this structural motif is highly 
conserved as it is part of several essential building blocks. Moreover, in the host bacteria 
may be confronted with a mixture of HDPs that work effectively in combination and some 
HDPs (e.g hBD3) seem to act by attacking multiple targets. 
1.7 Objectives of this work 
In times in which antibiotics are becoming increasingly ineffective, there is a need to 
search for new therapeutic agents. HDPs, ubiquitous in nature, are promising candidates 
for the development of novel anti-infective drugs since they combine direct antimicrobial 
activity with immunomodulatory functions. However, for systematic exploitation of this 
concept, we need to know more about both the molecular mechanisms underlying the 
immune modulation and the defined antibiotic activities of HDPs.  
Previous work has demonstrated that the antibacterial action of defensins can be much 
more targeted as it was originally proposed (compare section 1.3).  
This study was designed to gain further insights into the antibacterial mode of action of 
different defensin groups. For this purpose, the invertebrate defensin mechanism of action 
was analysed on the molecular level. Many invertebrate defensins show high sequence 
and structural similarity to the fungal defensin plectasin, raising the question if this 
correlates with a similar antibiotic action. Therefore, the interaction of three oyster 
defensin variants with the cell wall precursor lipid II was studied in vitro and in vivo. 
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Moreover, vertebrate θ-defensins were included in this study to investigate their mode of 
action against staphylococci. Interestingly, these peptides differ structurally from all other 
defensins since they consist of only 18 amino acids and their backbones are cyclised by 
peptide bonds. It should be found out if they also affect cell wall biosynthesis or if they 
target other cell envelope molecules.  
Since vertebrate defensins display – in comparison to plectasin – a broader activity 
spectrum and a lower lipid II affinity, the attraction to additional targets of Gram-negative 
bacteria was investigated. Hence, the interaction of hBD3 with the Gram-negative cell 
envelope was studied, including permeabilisation of the outer and inner membrane and 
susceptibility tests of E. coli mutants with different LPS structures.  
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2 Material and Methods 
2.1 Chemicals and solvents 
Table 1 Chemicals and solvents used in this study. 
Manufacturer Chemical/Solvent 
AppliChem, Darmstadt, Germany TEMED 
Avanti Polar Lipids, Alabaster, USA DOPC 
Becton Dickinson GmbH, Heidelberg, 
Germany 
Agar, BactoTM tryptone, Columbia agar with 5% 
sheep blood, Mueller-Hinton II Agar 
Bio-Rad, München, Germany Protein assay dye reagent concentrate 
Calbiochem®; Merck, Darmstadt, Germany CENTATM
 
β-lactamase substrate 
Fermentas GmbH, St. Leon-Rot, Germany BSA standard set; GeneJET
TM 
Plasmid Miniprep 
Kit, IPTG, Page Blue
TM
 Protein Staining Solution, 
Page Ruler
TM
 Protein Ladder (unstained, 
prestained), TopVision
TM
 Agarose 
GE Healthcare, Freiburg, Germany HBS buffer (10x), NaOH 
Hartmann Analytic GmbH, Braunschweig, 
Germany 
L-[
14
C]isoleucine, 2-[
14
C]thymidine, [
3
H]tetra-
phenylphosphonium bromide, 5-[
3
H]uridine 
InvitrogenTM, Darmstadt, Germany NuPAGE® LDS sample buffer (4x) 
Larodan Fine Chemicals, Malmö, Sweden C55-P 
Leica Microsystems, Bensheim, Germany Ultrostain 1H 
Oxoid, Wesel, Germany BHI, Mueller-Hinton broth, TSB, yeast extract 
Peqlab Biotechnologie, Erlangen, 
Germany 
PeqGold DNA ladder mix 
Pierce; Distributor: Thermo Fisher 
Scientific, Schwerte, Germany 
BCATM Protein Assay Kit 
Qiagen, Hilden, Germany Ni-NTA-Agarose 
Science Services, München, Germany EMbed 812 Embedding Kit, Kodak D-19 
developer, Agefix fixative solution 
Serva Electrophoresis GmbH, Heidelberg, 
Germany 
Acrylamide/bisacrylamide solution (19:1), 40% 
(w/v), anthrone 
Sigma-Aldrich, Taufkirchen, Germany Ammonium citrate, 6-aza-2-thiothymine, 
ammonium hydroxide, ascorbic acid, 
carboxyfluorescein, CHAPS, choline chloride, 
DNase I, ethidium bromide, glutaraldehyde 
(grade I, 70%), lead(II) citrate tribasic trihydrate, 
lipoteichoic acid (from S. aureus), lysozyme, 
MES, sephadex G-50, octyl-sepharose CL 4B, 
ONPG, osmium tetroxide solution (4%), pyridine, 
RNase A, Triton X-100, UDP-GlcNAc 
Zinsser Analytic, Frankfurt, Germany Filtersafe 
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All other chemicals and reagents not listed in this table were purchased from Merck 
(Darmstadt, Germany).  
2.2 Antibiotics and antimicrobial peptides 
Table 2 Antibiotics and antimicrobial peptides used in this study. 
Antibiotic/Peptide Solvent Source 
Ampicillin MilliQ water Sigma-Aldrich, Taufkirchen, Germany 
Cg-Defs MilliQ water Paulina Schmitt, University of 
Montpellier, France 
Chloramphenicol Ethanol Calbiochem®; Merck, Darmstadt, 
Germany 
Ciprofloxacin 
(Ciprobay® 200) 
Infusion solution 
(ready-to-use) 
Bayer Healthcare, Leverkusen, Germany 
Erythromycin Ethanol Calbiochem®; Merck, Darmstadt, 
Germany 
hBD3 MilliQ water Alessandro Tossi, University of Trieste, 
Italy 
Kanamycin MilliQ water Sigma-Aldrich, Taufkirchen, Germany 
Nisin 0.05% Acetic acid Michaele Josten, University of Bonn, 
Germany  
Penicillin G MilliQ water Sigma-Aldrich, Taufkirchen, Germany 
Pep5 MilliQ water Michaele Josten, University of Bonn, 
Germany 
Polymyxin B  MilliQ water Sigma-Aldrich, Taufkirchen, Germany 
Rifampicin MilliQ water Sigma-Aldrich, Taufkirchen, Germany 
RTD-1, RTD-2 MilliQ water Michael Selsted, University of Southern 
California, USA 
Spectinomycin MilliQ water Sigma-Aldrich, Taufkirchen, Germany 
Tetracycline Methanol Sigma-Aldrich, Taufkirchen, Germany 
Vancomycin MilliQ water Ratiopharm, Ulm, Germany 
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2.3 Microbiological methods 
2.3.1 Bacterial strains, culture media and growth conditions 
All bacterial strains used in this thesis are listed in Table 3. For long-term storage, glycerol 
stocks of the bacteria were prepared. Therefore, an overnight culture was mixed 1:1 with 
sterile glycerol (v/v) and stored in cryovials at -70°C. Strains were recovered from glycerol 
stocks as required by streaking out on appropriate agar plates and subsequent overnight 
incubation at 37°C. 
Unless otherwise indicated, the cultivation of liquid cultures was performed aerobically at 
37°C on an orbital shaker (170 rpm; TR-250; Infors-HF, Bottmingen, Switzerland) using a 
2% inoculum (v/v) from an overnight culture. Growth media used for bacterial cultivation 
are denoted in Table 4. 
Selective media were supplemented with antibiotics in the following concentrations: 
ampicillin (40 µg/ml), erythromycin (25 µg/ml), kanamycin (40 µg/ml), spectinomycin  
(25 µg/ml) and tetracycline (25 µg/ml).  
Staphylococcus carnosus TM300 harbouring the pAH-PepI vector was grown in presence 
of 1% xylose to induce pepI expression.  
 
Table 3 Bacterial strains and plasmids used in this thesis. 
Strain or plasmid Relevant characteristic(s) Reference/Source 
Gram-positive bacteria 
Staphylococcus aureus   
SG511-Berlin Mutation in gene graS Sass and Bierbaum, 2009 
SA113 Derivative of S. aureus NCTC 8325 Iordanescu and Surdeanu, 
1976 
SA113 ∆atl atlA deletion mutant of strain SA113 
(∆atlA::spc) 
Biswas et al., 2006 
SA113 ∆ypfP ypfP deletion mutant of strain SA113 
(∆ypfP::ermB) 
Fedtke et al., 2007 
SEJ1 Protein A deficient derivative of  
S. aureus RN4220, markerless 
deletion of spa 
Grundling and 
Schneewind, 2007a 
SEJ1 ∆ltaS (4S5) SEJ1-derived LTA-deficient 
suppressor strain 
Corrigan et al., 2011 
Staphylococcus simulans   
22 Indicator strain Sahl and Brandis, 1981 
Staphylococcus carnosus   
TM300 Indicator strain Schleifer and Fischer, 
1983 
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Table 3  continued 
Strain or plasmid Relevant characteristic(s) Reference/Source 
Micrococcus luteus   
DSM 1790 Indicator strain DSMZ 
Gram-negative bacteria 
Escherichia coli    
ATCC 25992 Indicator strain ATCC 
BL21(DE3) Expression host for cytoplasmic 
proteins; λDE3-lysogen, T7 RNA 
polymerase under control of lac 
promotor 
Studier and Moffatt, 1986 
BW25113 K-12 strain Datsenko and Wanner, 
2000 
BW25113 ∆waaG waaG deletion mutant of strain 
BW25113 (∆waaG::kan), lacks the LPS 
outer core  
Baba et al., 2006 
BW25113 ∆waaP waaP deletion mutant of strain 
BW25113 (∆waaP::kan); lacks LPS 
core phosphate 
Baba et al., 2006 
BW25113 ∆waaY waaY deletion mutant of strain 
BW25113 (∆waaY::kan), lacks one 
phosphate group in the LPS core 
region 
Baba et al., 2006 
ML-35pYC ∆lacI, constitutive β-galactosidase 
expression, plasmid-encoded (pBR-22) 
β-lactamase, Amp
R
 
Lehrer et al., 1988 
Plasmids   
pAH-PepI Xylose-inducible expression of pepI-gfp 
fusion gene, TetR 
Hoffmann et al., 2004 
pet21b-PBP2 pbp2 fused to C-terminal His6, Amp
R Körner, 2006 
 
The following strains tested for the antimicrobial activity of oyster defensins were provided 
by the Ifremer (French Research Institute for Exploration of the Sea, University of 
Montpellier, France): Bacillus megaterium CIP 6620, Escherichia coli SBS 363, Vibrio 
aestuarianus CIP 102971, Vibrio anguillarum ATCC 19264, Vibrio nigripulchtritudo CIP 
103195 and Vibrio splendidus CIP 107715. 
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Table 4 Culture media used in this thesis. 
Medium/Agar Source/Composition 
Columbia agar with 5% 
sheep blood 
Becton Dickinson GmbH 
Brain Heart Infusion 
(BHI) 
12.5 g brain infusion solids; 5 g beef heart infusion solids; 10 g 
proteose peptone; 2 g glucose; 5 g NaCl; 2.5 g Na2PO4; pH 7.4.  
37 g of the dehydrated medium (Oxoid) were dissolved in 1 l 
distilled water. 
Lysogeny Broth (LB) 10 g tryptone; 5 g yeast extract; 10 g NaCl; ad 1 l distilled water; 
pH 7.5; ± 14 g agar. 
Mueller-Hinton II Agar Becton Dickinson GmbH 
Mueller-Hinton Broth 300 g beef infusion; 17.5 g casein hydrolysate; 1.5 g starch;  
pH 7.3. 
21 g of the dehydrated medium (Oxoid) were dissolved in 1 l 
distilled water. 
Tryptone Soya Broth 
(TSB) 
17 g pancreatic digest of casein; 3 g pancreatic digest of soya 
bean; 5 g NaCl; 2.5 g K2HPO4; 2.5 g glucose; pH 7.3. 
30 g of the dehydrated medium (Oxoid) were dissolved in 1 l 
distilled water. 
2.3.2 Sterilisation of media, equipment and bacterial cultures 
Culture media, solutions, plastic vials and pipette tips were sterilised by autoclaving at 
121°C for 20 min (Varioklav
®
 75S; H+P Labortechnik AG, Oberschleißheim, Germany). 
Glassware was incubated in a sterilisator (Kelvitron® t; Heraeus, Langenselbold, 
Germany) for 4 h at 180°C. Bacterial cultures and contaminated labware were autoclaved 
at 134°C for 30 min. 
2.3.3 Determination of the optical density of a bacterial culture 
The cell number of a bacterial culture was determined by measuring the optical density 
(OD) at a wavelength of 600 nm in a spectrophotometer (UV-160; Shimadzu, Duisburg, 
Germany). For staphylococci an OD600 of 1 corresponds to 1-2x 10
9 cells/ml (Brotz, 1997), 
and for E. coli an OD600 of 1 corresponds to 5x 10
8 cells/ml (personal communication  
A. Tossi, University of Trieste).  
2.3.4 Determination of the minimal inhibitory concentration  
The minimal inhibitory concentration (MIC) is defined as the lowest concentration of an 
antimicrobial substance that will inhibit the visible growth of a microorganism. 
MIC determinations were carried out in 96-well polypropylene microtiter plates (NuncTM; 
Thermo Fisher Scientific, Schwerte, Germany) by standard broth microdilution using half-
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concentrated Mueller-Hinton broth or 10% Mueller-Hinton broth (diluted in 10 mM sodium 
phosphate buffer (SPB), pH 7.4). Test strains were grown to an OD600 of 1 and 
subsequently diluted to 1-2x 105 cells/ml. Then, 50 µl of the bacterial suspension were 
mixed with 50 µl of the peptide solution, and the inoculated microtiter plate was incubated 
for 10 min at RT on a microtiter shaker (Titertek; Flow Laboratories, Meckenheim, 
Germany). The MIC was read after 24 h of incubation at 37°C without agitation. The 
results given are mean values of at least two independent experiments performed in 
duplicate. 
2.3.5 Antagonisation of putative target molecules 
Different peptidoglycan precursors (C55-P, lipid II, UDP-MurNAc-pp and UDP-GlcNAc) as 
well as LTA from S. aureus were tested for antagonisation of defensin antimicrobial 
activity. Therefore, serial dilutions of defensins were performed from 0.25 to 8x MIC in a 
polypropylene microtiter plate (NuncTM; Thermo Fisher Scientific, Schwerte, Germany) 
with the potential antagonist in a 1:1, 1:2 or 1:4 molar ratio. S. aureus SG511-Berlin was 
then added to the microtiter plate as for a conventional MIC determination. After a 24 h-
incubation at 37°C, the lowest peptide/antagonist molar ratio that inhibited the 
antimicrobial activity of the highest defensin concentration (8x MIC) was determined.  
2.3.6 Bacterial killing kinetics  
S. aureus SG511-Berlin was grown in half-concentrated Mueller-Hinton broth to an OD600 
of 0.1. Defensins were added in concentrations corresponding to 5x or 10x MIC (as 
determined after 24 h). At defined time intervals, 40 µl aliquots of the culture were taken, 
diluted in 360 µl 10 mM potassium phosphate buffer (pH 7) and 100 µl of appropriate 
dilutions were plated in triplicate on Mueller-Hinton II agar plates (Becton Dickinson 
GmbH). The plates were incubated overnight at 37°C and the number of colony forming 
units (CFU) was calculated based on the respective dilution factor. An untreated culture 
was used as a control.  
2.3.7 Growth kinetic measurement 
Cells were grown in half-concentrated Mueller-Hinton broth to the exponential phase and 
then diluted to an OD600 of 0.2 in 10% Mueller-Hinton broth (in 10 mM SPB, pH 7.4). 
Afterwards, 100 µl of the cell suspension were added to 100 µl of various antimicrobial 
compounds at 5x MIC. OD600 measurements were performed on a microplate reader 
(SunriseTM; Tecan, Crailsheim, Germany) over a period of 6 h at 37°C. Obtained data 
were analysed by MagellanTM data analysis software (Tecan, Crailsheim, Germany).  
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For determination of IC50 values, a serial dilution of hBD3 (0-2 µM) was performed in 10% 
Mueller-Hinton broth (in 10 mM SPB, pH 7.4). Then, cells were added to a final 
concentration of 1x 106 cells/ml and the bacterial suspension was incubated on a 
microplate reader as described above. The IC50 value was defined as the concentration 
which inhibited 50% of bacterial growth. 
2.3.8 Potassium release from whole cells 
Potassium efflux of whole cells was monitored with a MI‐442 potassium electrode and a 
MI‐409F reference electrode (Microelectrodes Inc., Bedford, USA) connected to a 
microprocessor pH meter (pH 213; HANNA® Instruments, Kehl am Rhein, Germany). 
Before starting the measurement, the electrodes were pre-conditioned in choline buffer 
(300 mM choline chloride, 30 mM MES, 20 mM Tris; pH 6.5) for at least 1 h. Calibration of 
the electrodes was carried out before each determination using freshly prepared standard 
solutions containing 0.01, 0.1 and 1 mM KCl in choline buffer (see above).  
S. simulans 22 was grown in 50 ml half-concentrated Mueller-Hinton broth (± 10 mM 
glucose) at 37°C to an OD600 of 1 to 1.5. Then, cells were harvested by centrifugation 
(4,000 rpm, 3 min, 4°C), washed with 25 ml prechilled choline buffer and resuspended in 
choline buffer (± 10 mM glucose) to a final OD600 of 30. For each measurement, cells were 
diluted in choline buffer (± 10 mM glucose) to an OD600 of 3, and the potassium release 
was monitored for 5 min at RT. Defensins were added at 5x and 10x MIC. Potassium 
concentrations were calculated from the measured voltage according to Orlov et al. (2002) 
and expressed relative to the total amount of potassium released after addition of 1 µM of 
the pore-forming lantibiotic nisin (100% efflux).  
2.3.9 Determination of the membrane potential using tetraphenyl-
phosphonium bromide 
S. aureus SG511-Berlin was grown in half-concentrated Mueller-Hinton broth to an OD600 
of 0.5 to 0.6. To monitor the membrane potential, 1 µCi/ml of [3H]tetraphenylphosphonium 
bromide (TPP+; 26 Ci/mMol; Hartmann Analytic) was added (the lipophilic TPP+ diffuses 
across the bacterial membrane in response to a trans-negative membrane potential). The 
culture was treated with defensins at 10x MIC, sample aliquots of 100 µl were filtered 
through cellulose acetate filters (pore size 0.2 µm; WhatmanTM, Dassel, Germany) and 
washed twice with 5 ml of 50 mM potassium phosphate buffer (pH 7). The filters were 
dried, placed into 5 ml scintillation fluid (Filtersafe, Zinsser Analytic) and the radioactivity 
was measured with a liquid scintillation counter (Tri-Carb 1900CA; Packard, Downers 
Grove, USA) for 5 min per filter. Non specific TPP+ binding was determined by measuring 
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the TPP+ incorporation into cells treated with 10% butanol (v/v); the total radioactivity was 
measured using unfiltered 100 µl sample aliquots. The pore-forming lantibiotic nisin (40 
µg/ml corresponds to 10x MIC) was used as a control. For calculation of the membrane 
potential (), the TPP+ concentrations were applied into the Nernst equation  = (2.3 x 
R x T/F) x log (TPP+ inside/TPP+ outside), where T is the absolute temperature, R is the 
universal gas constant and F is the Faraday constant (according to Sahl, 1985).  
2.3.10 Incorporation of radio-labelled metabolites 
The effect of defensins on macromolecular synthesis was studied by monitoring the 
incorporation of [3H]- or [14C]-labelled precursors (2-[14C]thymidine, 5-[3H]uridine, L-
[14C]isoleucine; Hartmann Analytic) into S. aureus cells. Therefore, cultures of S. aureus 
SG511-Berlin were grown in half-concentrated Mueller-Hinton broth to an OD600 of 0.4, 
diluted 10-fold into fresh medium and allowed to regrow to an OD600 of 0.1. Subsequently, 
the respective labelled precursor was added to give a final concentration of 1 µCi/ml for 
3H-labelled metabolites and 0.1 µCi/ml for 14C-labelled metabolites. Cultures were then 
split; one culture was treated with defensins, another one was run as a control. Selectivity 
of incorporation was confirmed using antibiotics that inhibit specifially protein 
(tetracycline), RNA (rifampicin) or DNA synthesis (ciprofloxacin). 
Incorporation of the metabolites was monitored for up to 2 h. At certain time points, 
aliquots of 200 µl were taken and immediately added to 2 ml ice-cold 10% trichloroacetic 
acid. After 30 min incubation on ice, the samples were filtered through glass microfibre 
filters (WhatmanTM, Dassel, Germany) and washed with 5 ml 2.5% trichloroacetic acid. 
The dried filters were placed into 5 ml scintillation fluid (Filtersafe; Zinsser Analytic) and 
counts were obtained in a liquid scintillation counter (Tri-Carb 1900CA; Packard, Downers 
Grove, USA) for 5 min for each filter.  
2.3.11 Membrane permeabilisation assay 
The effect of defensins on the cell integrity of Gram-negative bacteria was determined 
photometrically by measuring the hydrolysis of the extracellular substrates CENTATM 
(Calbiochem®) and o-nitrophenyl-β-D-galactopyranoside (ONPG; Sigma-Aldrich) in E. coli 
ML35-pYC. The lactose permease-deficient strain contains a cytoplasmic β-galactosidase 
which accepts the lactose-mimic ONPG as substrate. ONPG is unable to cross the 
membrane and can only be hydrolysed in cells with damaged outer and inner membrane. 
Moreover, the strain harbours a plasmid-encoded periplasmic β-lactamase that hydrolyses 
the chromogenic cephalosporin CENTATM if the outer membrane is impaired.  
Material and Methods 25  
 
E. coli ML35-pYC was grown to early exponential phase and diluted to 1x 107 cells/ml in 
10% Mueller-Hinton broth (in 10 mM SPB, pH 7.4). Afterwards, 20 µl of the cell 
suspension were incubated with either 0.15 mM CENTA or 1.5 mM ONPG and different 
defensin concentrations in a final volume of 200 µl. Hydrolysis was measured at 405 nm 
at 37°C for 120 min on a microplate reader (SunriseTM; Tecan, Crailsheim, Germany). 
Obtained data were analysed by MagellanTM data analysis software (Tecan, Crailsheim, 
Germany).  
2.3.12 Intracellular accumulation of the final soluble cell wall precursor 
UDP-N-acetylmuramyl-pentapeptide  
UDP-N-acetylmuramyl-pentapeptide (UDP-MurNAc-pp) is the final soluble precursor of 
bacterial cell wall biosynthesis. Antibiotics such as vancomycin, that interfere with the late, 
membrane-bound steps of peptidoglycan synthesis, trigger the accumulation of this 
precursor in the cytoplasm which can be isolated and detected by HPLC (Kohlrausch and 
Holtje, 1991). 
For analysis of the cytoplasmic peptidoglycan precursor pool, S. aureus SG511-Berlin or  
S. simulans 22 was grown in half-concentrated Mueller-Hinton broth to an OD600 of 0.5 
and supplemented with 130 µg/ml of chloramphenicol. Chloramphenicol prevents the de 
novo synthesis of enzymes that may interfere, e.g. through induction of cellular autolysis, 
with the accumulation of the UDP-linked peptidoglycan precursor in the cytoplasm (Dai 
and Ishiguro, 1988). After 15 min of incubation, defensins or vancomycin, respectively, 
were added at 10x MIC (to a final volume of of 5 ml) and the samples were further 
incubated for 30 min. Then, cells were spun down (5,300 rpm, 15 min, 4°C), resuspended 
in 0.25 ml MilliQ water and treated with two volumes of boiling water for 15 min.  
The suspensions were cooled down and the cell extracts were adjusted to pH 2 by 
addition of H3PO4. Insoluble components were removed by centrifugation at 13,000 rpm 
for 5 min. The supernatants were filtered (Arodisc® syringe filter, pore size 0.2 µm; Pall, 
Dreieich, Germany) and analysed by reversed-phase high pressure liquid chromatography 
(RP-HPLC) in 50 mM sodium phosphate buffer pH 5.2, developed in an isocratic mode 
over 35 min at a flow rate 1 ml/min on a Nucleosil 100-C18 column (Schambeck SFD 
GmbH, Bad Honnef, Germany). UDP-linked cell wall precursors were detected at 260 nm 
and corresponding fractions were confirmed using matrix-assisted laser desorption 
ionisation time-of-flight mass spectrometry (MALDI-TOF MS; BiflexTM, Bruker Daltonics, 
Bremen, Germany) in a negative mode with 6-aza-2-thiothymine dissolved in 50% 
ethanol/20 mM ammonium citrate (v/v) as matrix. 
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2.4 Methods in molecular genetics 
2.4.1 Determination of concentration and purity of nucleic acids 
The concentration of nucleic acids was determined photometrically at 260 nm using a 
NanoDrop® ND-1000 spectrophotometer (Peqlab Biotechnologie, Erlangen, Germany). 
Purity was assessed by the ratio of absorbance at 260 nm and 280 nm (A260/A280). 
2.4.2 Agarose gel electrophoresis 
DNA fragments were analysed by standard agarose gel electrophoresis employing 0.8-2% 
agarose gels (w/v, Top VisionTM Agarose; Fermentas). Gels were run in 1x TAE buffer and 
the DNA was stained by incubating the gel 20-30 min in an ethidium bromide solution  
(1 µg/ml in 1 l MilliQ water). Subsequently, DNA bands were visualised using an 
ImageMaster® VDS (GE Healthcare/Pharmacia, Freiburg, Germany).  
2.4.3 Isolation of plasmid DNA 
2 to 5 ml of a bacterial overnight culture were harvested by centrifugation (13,000 rpm,  
5 min, RT) and plasmids were extracted using GeneJETTM Plasmid Miniprep Kit 
(Fermentas) according to the manufacturer´s instructions. Finally, plasmid DNA was 
eluted with 30 µl MilliQ water (70°C) and stored at -20°C until further use.  
2.4.4 Preparation of electrocompetent E. coli cells 
For preparation of electrocompetent cells, E. coli BL21(DE3) was grown in 500 ml LB at 
37°C to an OD600 of 0.5. Afterwards, the culture was incubated on ice for 15 min and 
subsequently harvested by centrifugation (6,000 rpm, 15 min, 4°C). Bacterial pellets were 
washed with 250 ml prechilled distilled water and 10 ml prechilled 10% glycerol (v/v). 
Finally, cells were resuspended in 800 µl prechilled 10% glycerol (v/v). Aliquots of 50 µl 
were frozen in liquid nitrogen and stored at -70°C until further use. 
2.4.5 Transformation of E. coli by electroporation 
Electrocompetent cells were thawed on ice and mixed with 1-2 µl plasmid DNA. After  
1 min incubation on ice, the cells were electroporated in a MicroPulserTM (program Ec2; 
Biorad, München, Germany) using a prechilled electroporation cuvette (2 mm gap). 
Immediately, cells were removed from the cuvette and resuspended in 1 ml LB to recover 
for 1 h at 37°C on a rotary shaker. 
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Finally, 100 µl of the diluted (1:10, 1:100; v/v) and undiluted bacterial solution were 
streaked out on LB agar plates containing the appropriate antibiotic.  
2.5 Protein and biochemical methods 
2.5.1 Heterologous expression and purification of His-tagged PBP2 
E. coli BL21(DE3) containing pet21b-PBP2 was grown in 1 l LB supplemented with  
40 µg/ml ampicillin at 37°C to an OD600 of 0.6. Protein expression was induced by addition 
of IPTG (Fermentas) in a final concentration of 1 mM. After 4 h incubation, cells were 
pelleted (7,000 rpm, 12 min, 4°C; Sorvall Evolution RC; Heraeus, Langenselbold, 
Germany) and resuspended in 20 ml lysis buffer (Table 5). Then, 200 µg/ml lysozyme,  
10 µg/ml RNase and 100 µg/ml DNase were added and cells were further incubated for 
30 min at 37°C. After sonication (8x 10 s intervals at 60% including 15 s of cooling on ice; 
Sonifier® W250; G. Heinemann, Schwäbisch Gmünd, Germany), the cell debris was 
removed by centrifugation (10,300 rpm, 20 min, 4°C) and the supernatant was applied to 
1.5 ml Ni-NTA-agarose (Qiagen) and incubated overnight at 4°C under stirring. The batch 
was transferred to a polypropylene column (Qiagen, Hilden, Germany) and washed with 
10 ml lysis buffer and 5 ml washing buffer (Table 5) to remove weakly bound material. 
Recombinant proteins were eluted with 3 ml elution buffer (Table 5) in six fractions of  
500 µl, mixed 1:1 with sterile glycerol (v/v) and stored at -20°C. Protein-containing 
fractions were pooled and dialysed using Slide-A-Lyzer dialysis cassettes (Pierce; Thermo 
Fisher Scientific, Schwerte, Germany). 
 
Table 5 Buffers used for protein purification. 
Buffer Chemical ingredients 
Lysis buffer 50 mM Tris-HCl (pH 7.5); 0.5 M NaCl; 1% Triton X-100 (v/v); 
10 mM imidazole 
Washing buffer 50 mM Tris-HCl (pH 7.5); 0.5 M NaCl; 1% Triton X-100 (v/v); 
20 mM imidazole 
Elution buffer 50 mM Tris-HCl (pH 7.5); 0.5 M NaCl; 1% Triton X-100 (v/v); 
200 mM imidazole 
Dialysis buffer 50 mM Tris-HCl (pH 7.5); 0.5 M NaCl; 1% Triton X-100 (v/v). 
 
2.5.2 Sodium-dodecyl-sulfate polyacrylamide gel electrophoresis 
Purified proteins were analysed by discontinuous sodium-dodecyl-sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE; Table 6). Therefore, proteins were mixed with 4x 
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NuPAGE® LDS sample buffer (Invitrogen) and incubated for 5 min at 95°C prior to loading. 
The gel was run in Tris-glycine buffer (25 mM Tris; 192 mM glycine; 0.1% SDS (w/v);  
pH 8.5) in a Mini-Protean II Electrophoresis Cell (Bio-Rad, München, Germany) at 100 V 
for the stacking gel and 120 V for the resolving gel. Protein bands were visualised using 
PageBlueTM protein staining solution (Fermentas) according to the manufacturer´s 
instructions. 
 
Table 6 Chemical ingredients for one resolving and one stacking gel. 
Chemicals Resolving gel (12%) Stacking gel (4%) 
Distilled water 3.845 ml 1.865 ml 
3 M Tris, pH 8.5 1.25 ml - 
0.1 M Tris, 0.8% SDS (w/v) - 0.3 ml 
20% SDS (w/v) 0.05 ml - 
APS (21 mg/ml) 0.2 ml 0.08 ml 
TEMED 0.005 ml 0.005 ml 
40% acrylamide/bisacrylamide (w/v) 2.25 ml 0.25 ml 
2.5.3 Zymogram analysis 
Cell wall lytic enzymes in the supernatant of RTD- and Pep5-treated cells were analysed 
by zymograms. For this, S. aureus SG511-Berlin was grown in half-concentrated Mueller-
Hinton broth to an OD600 of 0.6. Then, cells were harvested by centrifugation (4,000 rpm,  
5 min, 4°C) and washed three times with 10 mM SPB (pH 7.4). Finally, cells were 
resuspended in 10% Mueller-Hinton broth (in 10 mM SPB, pH 7.4) and aliquots of 2.5 ml 
were incubated with peptides corresponding to 10x MIC. After incubation for 30 or 60 min, 
cells were pelleted (10,000 rpm, 5 min, 4°C). The supernatant containing released 
proteins was concentrated to a volume of 50 µl using VivaSpin-columns (MWCO 3,000; 
Sartorius, Göttingen, Germany) according to the manufacturer´s instructions. 
Subsequently, 25 µl of the enzyme extract were loaded onto a 12% polyacrylamide gel 
containing heat-killed M. luteus DSM 1790 cells as substrate. After run, the gel was 
washed three times with distilled water for 15 min before an overnight incubation in buffer  
(50 mM Tris-HCl, pH 7.5; 10 mM CaCl2, 10 mM MgCl2, 0.1% Triton X-100, v/v) at 37°C. 
Lytic activity was observed as clear zones against an opaque background. To gain a 
higher contrast, gels were stained with 0.1% methylene blue (w/v) for 15 min and washed 
with distilled water until clear bands became visible. 
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2.5.4 Determination of peptide and protein concentration 
2.5.4.1 Bradford assay 
The total protein concentration was measured using protein assay dye reagent (Bio-Rad, 
München, Germany) as recommended by the manufacturer. The assay is based on the 
absorbance shift of Coomassie Brilliant Blue G-250 bound to basic and aromatic amino 
acid residues. The absorption at 595 nm was measured with a spectrophotometer (UV-
160; Shimadzu, Duisburg, Germany). A standard curve was obtained using different 
dilutions (0.125-2 mg/ml) of bovine serum albumin (BSA; Fermentas). 
2.5.4.2 BCA protein assay 
As detergents and some buffers interfere with the Bradford assay, protein concentrations 
were alternatively determined using the BCATM Protein Assay Kit (Pierce) according to the 
manufacturer´s instructions. This quantification is based on the reduction of copper (II) 
ions that form a violet-coloured complex in alkaline solution. The absorption was 
measured with a NanoDrop® ND-1000 spectrophotometer (program: protein BCA; Peqlab 
Biotechnologie, Erlangen, Germany) at 562 nm. A standard curve was obtained using 
different concentrations (5-250 µg/ml) of BSA. 
2.5.5 Peptide quantification by spectrometry  
The spectrophotometer NanoDrop® ND-1000 (program: protein A280; Peqlab 
Biotechnologie, Erlangen, Germany) was used to measure peptide concentrations based 
on the molecular weight and extinction coefficient of the sample. 
2.5.6 In vitro lipid II synthesis and purification 
The cell wall precursor lipid II was synthesised in vitro using membrane preparations of  
M. luteus DSM 1790 containing the enzymes MraY and MurG and by external addition of 
the lipid carrier C55-P. 
2.5.6.1 Membrane preparation of Micrococcus luteus DSM 1790  
For membrane preparation, 2 l TSB were inoculated with M. luteus DSM 1790 and 
incubated overnight at 37°C in a water bath (120 rpm). The following day, cells were 
harvested by centrifugation (8,000 rpm, 10 min, 4°C; Sorval Evolution RC; Heraeus, 
Langenselbold, Germany) and washed with 300 ml buffer (50 mM Tris-HCl; 10 mM MgCl2; 
pH 7.5). Then, cells were resuspended in 100 ml buffer containing 400 µg/ml lysozyme 
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and 10 µg/ml DNase, and incubated on ice for 1 to 2 h. The cell suspension was 
subsequently warmed up to 35°C, cooled on ice again and membranes were centrifuged 
(18,000 rpm, 20 min, 4°C; Sorvall Evolution RC; Heraeus, Langenselbold, Germany). 
Finally, the pellets were resuspended in 8 ml buffer (see above) and stored at -70°C until 
further use. 
2.5.6.2 Extraction of UDP-MurNAc-pp 
S. simulans 22 was grown in 3 l Mueller-Hinton broth to an OD600 of 0.75 and 
supplemented with 130 µg/ml chloramphenicol. After 15 min incubation, vancomycin was 
added in a final concentration of 5 µg/ml and the cells were further incubated for 60 min. 
Afterwards, the cells were harvested by centrifugation (8,000 rpm, 10 min, 4°C; Sorvall 
Evolution RC; Heraeus, Langenselbold, Germany) and the pellet was resuspended in  
20 ml MilliQ water. The cell wall precursor UDP-MurNAc-pp was extracted with two 
volumes of boiling water. Finally, the suspension was cooled down, cell debris was 
removed by centrifugation (18,000 rpm, 30 min, 4°C; Sorvall Evolution RC; Heraeus, 
Langenselbold, Germany) and the supernatant was lyophilised (Alpha 2-4 LSC; Christ, 
Osterode am Harz, Germany). The lyophilisate was dissolved in 4 ml MilliQ water and 
added to the in vitro lipid II synthesis (section 2.5.6.3). 
2.5.6.3 In vitro lipid II synthesis 
Initially, the lipid II synthesis was performed in an analytical scale (in a total volume of  
75 µl) to find the optimal conditions as membrane preparations can vary in their synthesis 
rate (Table 7). Therefore, C55-P (dissolved in methanol:chloroform, 1:1, v/v) was vacuum-
dried and redissolved by addition of Triton X-100 (Table 7). After addition of the isolated 
membranes, the other ingredients were added in the following order: Tris-HCl, UDP-
GlcNAc, MgCl2 and UDP-MurNAc-pp (Table 7). The reaction mixture was subsequently 
incubated for 2 h at 30°C in a water bath. Bactoprenol-containing products were extracted 
with the same volume n-butanol/pyridine acetate (2:1, v/v; pH 4.2) and analysed by thin-
layer chromatography (TLC). For the extraction solution 6 M glacial acetic acid was 
adjusted to pH 4.2 by addition of pyridine and mixed with two volumes of n-butanol. 
After centrifugation (13,000 rpm, 3 min), 20 µl of the upper (butanol) phase were spotted 
on a silica gel (TLC Silica Gel 60 F254; Merck, Darmstadt, Germany) and separated using 
chloroform:methanol:water:concentrated ammonium hydroxide (88:48:10:1, v/v/v/v) as the 
solvent (Rick et al., 1998). Lipid spots were visualised by PMA staining reagent (2.5% 
phosphomolybdate (w/v), 1% ceric sulfate (w/v), 6% sulphuric acid (v/v)). For this, the TLC 
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plate was dipped into PMA solution, dried and developed by heating at 140°C until dark 
blue spots appeared. 
For synthesis and purification of milligram quantities of lipid II, the analytical procedure 
was scaled up by a factor of 250. After incubation of the reaction mixture, the butanol 
phase containing lipid II was collected, subsequently washed (8,000 rpm, 5 min, 4°C) with 
an equal volume of cold MilliQ water (pH 4.2) and purified as described below (section 
2.5.6.4). 
 
Table 7  Reaction mixture of lipid II synthesis (analytical scale). 
Ingredients Volume (µl) 
1 mM C55-P 5  
4% Triton X-100 10  
UDP-MurNAc-pp 5-10 
10 mM UDP-GlcNAc 7.5 
1 M Tris-HCl, pH 8 5  
1 M MgCl2 0.4 
Membrane preparation of M. luteus DSM 1790 5-20 
MilliQ water ad 75 
2.5.6.4 Purification of lipid II by HPLC 
Lipid II was applied to a Hi-Trap DEAE column (5 ml; Amersham Biosciences, Freiburg, 
Germany) equilibrated with buffer A (chloroform:methanol:water, 2:3:1, v/v/v) with a flow 
rate of 3 ml/min. After sample application, the flow rate was set to 5 ml/min and the 
column was washed with buffer A for 30 min. Lipid II was eluted in a linear ammonium 
biocarbonat gradient (0-25% buffer B; chloroform:methanol:NH4HCO3, 2:3:1, v/v/v). 5 ml-
fractions were collected and analysed by TLC as described above (section 2.5.6.3). 
Fractions containing lipid II were combined and concentrated using a rotary vacuum 
evaporator (Rotavapor RE11; Büchi Labortechnik, Flawil, Switzerland). Finally, lipid II was 
lyophilised, dissolved in chloroform:methanol (1:1, v/v) and stored in glas vials at -20°C. 
The lipid II concentration was determined by the phosphate content (section 2.5.7).  
2.5.7 Phosphate determination 
Phosphate determination was performed according to the method of Rouser (1970). For 
this, lipid samples were transferred to phosphate-free glass tubes and dried at 140°C for 
20 min. Afterwards, 0.3 ml HClO4 (70%, v/v) were added, and the tubes were incubated in 
a block heater at 180°C for 1 to 3 h. After cooling to RT, released inorganic phosphate 
32 Material and Methods 
 
was reduced by addition of 1 ml MilliQ water, 0.4 ml ammonium molybdate (1.25%, w/v) 
and 0.4 ml of freshly prepared ascorbic acid (5%, w/v), followed by incubation in boiling 
water for 5 min. The absorption of the formed, blue-coloured complex was read at  
795 nm. Phosphate concentrations of the samples were calculated by using a standard 
curve of 0-90 nmol inorganic phosphate (stock solution: 1 mM KH2PO4).  
2.5.8 Inhibition of PBP2-catalysed reaction in vitro 
The inhibition of the enzymatic activity of PBP2 in vitro was determined by incubating  
2 nmol lipid II with 7.5 µg PBP2-His6 in 10 mM MES (pH 5.5) in a final volume of 50 µl. 
Peptides were added in molar ratios ranging from 0.5 to 2 with respect to lipid II. The 
reaction mixtures were incubated at 30°C for 2 h and lipids were extracted by addition of 
one volume n-butanol/pyridine acetate (2:1, v/v) as described above (section 2.5.6.3).  
20 µl of the upper phase were spotted onto a TLC plate (TLC Silica Gel 60 F254; Merck, 
Darmstadt, Germany) and run in chloroform:methanol:water:ammonium hydroxide 
(88:48:10:1, v/v/v/v). Lipid bands were visualised by PMA staining (compare section 
2.5.6.3). 
2.5.9 Complexation of lipid II  
Lipid II (2 nmol) was vacuum-dried for 5 min at RT and Cg-Defh2 in aqueous solution was 
added in molar ratios ranging from 0.1 to 1 with respect to the amount of lipid II. Reaction 
mixtures were vortexed and incubated at 30°C for 30 min and then applied onto TLC 
plates (TLC Silica Gel 60 F254; Merck, Germany, Darmstadt). Plates were developed in 
butanol:acetic acid:water:pyridine (15:3:12:10, v/v/v/v) and stained with PMA (compare 
section 2.5.6.3). 
2.5.10 Transmission electron microscopy  
Cells were grown in half-concentrated Mueller-Hinton broth to an OD600 of 0.6. Aliquots of 
5 ml were exposed to defensin (at 10x MIC) for 30 min or 60 min at 37°C. Afterwards, the 
bacteria were harvested by centrifugation (5,000 rpm, 5 min, 4°C), resuspended in  
0.1 M SPB (pH 7.4) containing 3% glutaraldehyde (v/v; Sigma-Aldrich) and fixed overnight 
at 4°C. After washing the cells three times for 10 min with 0.1 M SPB (pH 7.4), they were 
postfixed in 2% phosphate-buffered osmium tetroxide (v/v; Sigma-Aldrich) at 4°C for 2 h. 
Subsequently, the samples were dehydrated with increasing concentrations of ethanol 
beginning with 30%. The dehydrated cells were incubated three times in propylene oxide 
for 5 min, followed by a treatment with a 1:1 mixture of polypropylene oxide and epon (v/v) 
overnight at RT. Finally, cells were embedded in epon using the EMbed-813 Embedding 
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Kit (Science Services, München, Germany) and incubated for polymerisation at 60°C for 
48 h. Thin sections (60 nm) were obtained with a ultramicrotome (Ultracut R; Leica 
Microsystems, Bensheim, Germany) using a diamond knife (2 mm, 45°; Science Services, 
München, Germany).  
The sections were transferred to copper grids (G200H-Cu; 3.05 mm; Science Services, 
München, Germany) and contrasted with 3% uranyl acetate (Ultrostain 1H; Leica 
Microsystems) and 0.3% lead citrate (10 ml distilled water; 30 mg lead(II) citrate tribasic 
trihydrate; 0.1 ml 10 M NaOH).  
The sections were examined with an EM900 electron microscope (Zeiss; Oberkochen, 
Germany) at 50 kV.  
For film developing, the negatives (Electron image film SO-163; Kodak; Science Services, 
München, Germany) were first placed into developer (Kodak D-19; Science Services) for 
10 min, and subsequently rinsed with distilled water. Afterwards, they were incubated in a 
fixative solution (Agefix; Science Services) for 10-15 min, followed by incubation in a 
water tank for 20-25 min.  
2.5.11 Biomolecular interaction analysis by surface plasmon resonance 
The interaction between defensins and lipid II was analysed with a Bicacore® system 
which allows analysis of biomolecular interactions in real time based on a surface 
plasmon resonance (SPR). For this, one interaction partner is attached to the surface of a 
sensor chip (ligand), whereas the other interaction partner (analyte) is passed in solution 
over the surface with the immobilised ligand. The interaction between ligand and analyte 
generates a response which is proportional to the change in mass. In a sensogram the 
response (given in response units, RU; 1 RU = 1 pg/mm2) is plotted against time. 
Binding studies between Cg-Defs and lipid II were carried out on a Biacore® 2000 
instrument (GE Healthcare, Freiburg, Germany) at 25°C. Therefore, a L1 sensor chip (GE 
Healthcare, Freiburg, Germany) was coated with lipids prepared as follows. Two kinds of 
small unilamellar vesicles (SUV) were prepared by sonication from 100% pure DOPC 
(1,2-dioleoyl-sn-glycero-3-phosphocholine; Avanti polar lipids) and from a mixture 
composed of DOPC and lipid II in a 99.2:0.8 molar ratio. SUV were coated on flow cell 1 
and 2, respectively. Prior to immobilisation, the chip surface was cleaned by injection of  
20 mM CHAPS for 5 min at a flow rate of 10 µl/min, followed by a 1 min injection of 30% 
ethanol at 10 µl/min. SUV were injected at 2 µl/min. To remove loosely bound vesicles, 
the surface was washed with 10 mM NaOH for 1 min at 100 µl/min. A short injection of 
BSA (100 µg/ml) at 30 µl/min was used to cover all non-specific binding sites. The coating 
of the lipid layers gave a response in the range of 6,000 to 6,500 RU. For kinetics, 
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peptides were simultaneously injected at 250 nM on the two flow cells at a flow rate of  
30 µl/min. Dissociation was monitored over 400 s in HBS running buffer (10 mM HEPES 
pH 7.4; 300 mM NaCl; GE Healthcare). New lipid layers were prepared for every injection 
to avoid the need for a regeneration step. The response of peptide binding on DOPC 
layers was taken as a negative control and subtracted from the response on lipid II-
containing DOPC layers. To determine the binding ratio, RU levels were measured at the 
plateau, just after the end of injection for the three defensins, nisin and tachyplesin. Two 
separate experiments were performed for each peptide injected. 
2.5.12 Chromatographic purification of lipoteichoic acid  
The extraction and purification of lipoteichoic acid (LTA) of S. aureus SG511-Berlin was 
performed according to the protocol of Grundling and Schneewind (2007b) with some 
modifications.  
Cells were grown in 3 l BHI overnight at 37°C in a water bath (120 rpm). The following 
day, the bacteria were harvested by centrifugation (7,000 rpm, 15 min, RT) and washed 
with 0.1 M sodium citrate (pH 4.7). For LTA extraction, cells were lysed in a Precellys® 24 
homogeniser (6,500 rpm, 3x 30 s, 30 s break; Peqlab Biotechnologie, Erlangen Germany) 
using the Precellys® glas kit (0.1 mm; Peqlab Biotechnologie, Erlangen, Germany). Glas 
beads were pelleted by centrifugation (7,000 rpm, 5 min) and the supernatant containing 
bacterial debris was centrifuged at 13,000 g for 60 min (Sorvall Evolution RC; Heraeus, 
Langenselbold, Germany). Then, the pellets were washed with 40 ml 0.1 M sodium citrate 
buffer (pH 4.7), centrifuged as described above and finally resuspended in 20 ml sodium 
citrate buffer (pH 4.7). The suspension was mixed with an equal volume of 1-butanol and 
incubated at RT for 30 min under stirring. After centrifugation (13,000 g, 20 min, RT; 
Sorvall Evolution RC), the aqueous (lower) phase containing LTA was dialysed against  
20 mM sodium citrate (pH 4.7) using Slide-A-Lyzer dialysis cassettes (2,000 MWCO; 
Thermo Fisher Scientific, Schwerte, Germany). 
Hydrophobic chromatography was executed on an octyl-sepharose CL 4B column 
(diameter: 1.6 cm, radius: 0.8 cm, length: 24 cm) equilibrated with 0.1 M sodium citrate 
(pH 4.7) in 15% propanol (v/v). The LTA-containing lysate was adjusted to 15% 1-
propanol (v/v) and subjected to the column with a flow rate of 0.3 ml/min. After sample 
application, the column was washed overnight with 0.1 M sodium citrate (pH 4.7) in 15% 
propanol at the same flow rate. LTA was eluted using a 300 ml gradient of 15-80%  
1-propanol in 0.1 M sodium citrate (pH 4.7) with a flow rate of 0.3 ml/min. 5 ml fractions 
were collected and analysed by their phosphate content (section 2.5.7). All phosphate-
containing fractions were combined and dialysed against 0.1 M sodium citrate (pH 4.7). 
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Afterwards, the LTA were concentrated to a volume of 5 ml using VivaSpin columns (15R, 
MWCO 2,000; Sartorius, Göttingen, Germany) and stored at -20°C until further use. 
2.5.13 Determination of glucose concentration 
The glucose concentration of the isolated LTA was determined by the anthrone method 
according to Herbert et al. (1971). For this, 0.2 ml of sample and standard solutions (20-
100 µg glucose) were chilled on ice and subsequently mixed with 1 ml freshly prepared 
anthrone reagent (200 mg anthrone; 5 ml ethanol; 95 ml 75% H2SO4, v/v). Afterwards, the 
tubes were incubated in a block heater at 100°C for 10 min. After cooling, the absorbance 
was read at 625 nm. 
2.5.14 CF-efflux from LTA-containing liposomes 
Vesicles were made of pure DOPC or DOPC supplemented with 0.5 mol% LTA (referring 
to the total amount of phospholipids). For this, 4 µM DOPC (dissolved in 
chloroform:methanol, 1:1, v/v) were mixed with LTA in a round bottom flask and the 
solvent was evaporated under a nitrogen stream. Final traces of solvents were removed in 
a dessicator for further 2 h and the dried lipid films were stored at -20°C until further use. 
The lipids were resuspended in 600 µl buffer (50 mM MES-KOH; 100 mM K2SO4; pH 6 or 
10 mM Tris-HCl; 0.85% NaCl; pH 7.2) containing 50 mM carboxyfluorescein (CF) and the 
flask was subsequently placed on a rotary evaporator (without a vacuum; Rotavapor 
RE11; Büchi Labortechnik, Flawil, Switzerland) spinning for 30-60 min in a water bath at 
30°C. The obtained multilamellar vesicles were subjected to 6 to 8 cycles of freeze-thaw, 
and then additionally passed 19 times through a polycarbonate filter (0.4 µm; WhatmanTM, 
Dassel, Germany) in an extrusion apparatus (Mini-Extruder; Avanti Polar Lipids, 
Alabaster, USA). Liposomes were separated from unencapsulated CF by gel filtration 
using sephadex G-50 (Sigma-Aldrich). Therefore, 2 ml of sephadex G-50 (equilibrated in 
buffer) were placed into polypropylene columns (Qiagen, Hilden, Germany) and 
centrifuged at 750 g for 3 min. The liposomes were subsequently applied to the column 
and centrifuged as described above. This procedure was repeated until the flow-through 
containing the vesicles was almost colourless. 
Then, the CF-loaded vesicles were diluted in 1.5 ml buffer (see above) at a final 
concentration of 25 μM phospholipid on a phosphorous base. The fluorescence intensity 
was measured at 520 nm (excitation at 492 nm) on a RF-5301 spectrophotometer 
(Shimadzu, Duisburg, Germany) for 3 min at RT. Peptides were added after 25 s at 
concentrations of 1 µM. To determine 100% marker release, 20 µl of 20% Triton X-100 
(v/v) were added at the end of each measurement. 
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3 Results 
3.1 Part 1: Insight into invertebrate defensin mode of action 
Defensins have been found in different phylogenetic groups of invertebrates. Interestingly, 
they can be classified according to their activity spectrum: antibacterial versus antifungal 
(Bulet et al., 2004). 
To investigate the mechanism of action of antibacterial invertebrate defensins, a 
comparative study with three defensin variants (Cg-Defs) produced by the Pacific oyster 
Crassostrea gigas was performed in collaboration with Delphine Destoumieux-Garzón 
(University of Montpellier, France). Cg-Defh1 and Cg-Defh2 were isolated from the 
hemocytes (Gonzalez et al., 2007a), whereas Cg-Defm was identified from the oyster 
mantle (Gueguen et al., 2006). The oyster defensins consist of 43 amino acid residues 
and have a net charge of +1 to +3 (Figure 6). Cg-Defh1 and Cg-Defh2 share 84% and  
79% sequence identity with Cg-Defm.  
 
 
 
Figure 6 A: Amino acid sequence alignment, molecular weights and net charges (at pH 7) of three 
defensins produced by the oyster C. gigas (Cg-Defs). Residues with a positive charge are 
marked in red, negatively charged residues are marked in blue. 
B: The 3D structure of Cg-Defm. The defensin adopts a cysteine-stabled α-helix β-sheet 
structure (CSαβ) in solution; the four disulphide bridges are marked in yellow (Schmitt et al., 
2012b). 
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The oyster defensins adopt a typical CSαβ fold in solution also found in defensins from 
plants and fungi. In contrast to other invertebrate defensins, they possess four disulphide 
bonds (C1-C5, C2-C6, C3-C7, C4-C8) which probably confer a more stable structure 
under high-osmolarity sea water conditions (Figure 6). 
3.1.1 Antibacterial activity spectrum of oyster defensins 
The three oyster defensin variants, Cg-Defh1, Cg-Defh2 and Cg-Defm, were expressed 
as recombinant peptides in E. coli and then tested for their antimicrobial activity in a 
standard broth microdilution assay. All oyster defensins were active at low micromolar 
concentrations against the Gram-positive bacteria tested (Table 8), but did not show 
significant antimicrobial activity against Gram-negative bacteria, including the oyster 
pathogens V. splendidus and V. aestuarianus (Table 8). Interestingly, Cg-Defh2 was the 
most potent peptide, exhibiting 2- to 4-fold lower MIC values than Cg-Defh1 and Cg-Defm 
against the tested Gram-positive strains. 
 
Table 8 Antimicrobial activity of the three oyster defensins Cg-Defh1, Cg-Defh2 and Cg-Defm. MIC 
values (µM) are expressed as the lowest concentration that caused visible growth inhibition. 
 
 Cg-Defh1 Cg-Defh2 Cg-Defm 
Gram-positive bacteria    
B. megaterium CIP 6620 0.06 0.03 0.03 
S. aureus SG511-Berlin 0.5 0.125 0.25 
S. simulans 22 2 0.5 1 
S. haemolyticus 6 2 2 
Gram-negative bacteria    
E. coli SBS 363 40 20 20 
V. aestuarianus CIP 102971 >40 >40 >40 
V. anguillarum ATCC 19264 >40 >40 >40 
V. nigripulchritudo CIP 103195 >40 >40 >40 
V. splendidus CIP 107715 >40 >40 >40 
 
3.1.2 Impact of oyster defensins on the membrane integrity of S. aureus 
To test whether oyster defensins have deleterious effects on the membrane of Gram-
positive bacteria, the membrane potential of S. aureus SG511-Berlin exposed to oyster 
defensins was determined. The membrane potential was monitored for a period of 20 min 
after peptide addition from the distribution of the lipophilic cation 
[3H]tetraphenylphosphonium bromide (TPP+) inside and outside the bacterial cells after 
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treatment. The pore-forming peptide nisin was used as a positive control. Oyster 
defensins did not cause any change in membrane potential when used at 10x MIC (Figure 
7). In contrast, the addition of nisin at 10x MIC (40 µg/ml) induced a significant decrease 
of the membrane potential of S. aureus SG511-Berlin (Figure 7). Altogether, these data 
indicate that at lethal concentrations, oyster defensins do not compromise the membrane 
integrity of S. aureus. 
 
 
Figure 7 Influence of oyster defensins on the membrane potential of S. aureus SG511-Berlin. Cells 
were incubated with 10x MIC of Cg-Defs or the pore-forming lantibiotic nisin. The membrane 
potential was calculated from the distribution of the lipophilic cation 
[
3
H]tetraphenylphosphonium bromide (TPP
+
) inside and outside the cells. TPP
+
 
concentrations were inserted into to the Nernst equation. Arrows indicate the moment of 
peptide addition. 
3.1.3 Accumulation of the soluble cell wall precursor UDP-N-
acetylmuramyl-pentapeptide in oyster defensin treated cells 
As the antibacterial activity of oyster defensins was mostly directed against Gram-positive 
bacteria (Table 8), the potential interference of the peptides with the peptidoglycan 
biosynthesis was investigated. The biosynthesis consists of a series of cytoplasmic 
reactions yielding soluble UDP-linked precursors of peptidoglycan, followed by 
membrane-bound steps, which starts with the anchoring of the last soluble precursor, 
UDP-N-acetylmuramyl-pentapeptide (UDP-MurNAc-pp), to the lipid carrier undecaprenyl 
phosphate (C55-P).  
To analyse the interference of oyster defensins with peptidoglycan biosynthesis, the 
accumulation of UDP-MurNAc-pp was monitored. Therefore, the cytoplasmic pool of 
soluble peptidoglycan precursors in cell extracts of defensin-treated S. simulans 22 was 
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analysed. RP-HPLC and mass spectrometry analysis of bacterial cell extracts showed that 
the three oyster defensins caused the intracellular accumulation of UDP-MurNAc-pp in a 
similar manner to vancomycin, which is known to form a complex with the cell wall 
precursor lipid II (Figure 8).  
 
 
Figure 8 Intracellular accumulation of the ultimate soluble cell wall precursor UDP-MurNAc-pp in 
S. simulans 22 treated with oyster defensins. S. simulans 22 was exposed to vancomycin 
(positive control; A) or Cg-Defs (B) at 10x MIC. Treated cells were extracted with boiling 
water and the cytoplasmic pool was analysed by RP-HPLC. Intracellular accumulation of 
UDP-MurNAc-pp (arrow) was confirmed by mass spectrometry (C; calculated monoisotopic 
mass 1149.35); in addition the mono- and disodium salts were detected.  
 
The continuous biosynthesis and subsequent defensin-induced accumulation of UDP-
MurNAc-pp in the cytoplasm is indicative of the absence of leakage and therefore 
consistent with the absence of membrane damage observed (Figure 7). Moreover, it 
strongly suggests that oyster defensins are inhibitiors of peptidoglycan biosynthesis. As 
the synthesis of UDP-MurNAc-pp itself is not impaired by oyster defensins, the cells 
cannot be de-energised and the inhibition may occur at the membrane-bound steps of the 
biosynthesis. 
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3.1.4 Antagonisation of antibacterial activity of oyster defensins 
Antagonisation assays were performed to identify the putative targets of oyster defensins 
in peptidoglycan biosynthesis. Briefly, peptidoglycan synthesis occurs as follows: After the 
anchoring of UDP-MurNAc-pp to C55-P, the resulting lipid I is converted into lipid II by 
addition of GlcNAc. Lipid II is subsequently translocated across the cytoplasmic 
membrane to the outer leaflet and incorporated into the growing peptidoglycan network by 
the activity of penicillin binding proteins (PBPs; Figure 27). Therefore, several 
intermediates of the peptidoglycan biosynthesis (namely lipid II, C55-P, UDP-MurNAc-pp 
and UDP-GlcNAc) were used as potential antagonists in liquid growth inhibition assays. 
Lipid II was the only compound that prevented the oyster defensin antimicrobial activity 
(Table 9). Indeed, when used at 1:1 molar ratio, oyster defensins became unable to inhibit 
growth of S. aureus SG511-Berlin at concentrations as high as 8x MIC. Neither activated 
cell wall sugars (UDP-MurNAc-pp and UDP-GlcNAc) nor the lipid carrier C55-P had similar 
antagonistic effects. This strongly suggests that the oyster defensins bind to the cell wall 
precursor lipid II. 
 
Table 9 Antagonisation of the antimicrobial activity of oyster defensins against S. aureus SG511-
Berlin by putative target molecules of cell wall biosynthesis. The following symbols are used: 
+ for antagonisation; - for normal antimicrobial activity. 
 
Antagonist Cg-Defh1 Cg-Defh2 Cg-Defm Molar ratio 
antagonist:Cg-Defs 
C55-P - - - - 
lipid II + + + 1:1 
UDP-MurNAc-pp - - - - 
UDP-GlcNAc - - - - 
 
3.1.5 Binding of oyster defensins to lipid II 
To further analyse the binding of oyster defensins to lipid II, the effect of Cg-Defs on the 
PBP2-catalysed reaction was determined in vitro. PBP2 is a bifunctional enzyme 
(transpeptidase and transglycosylase) that transforms monomeric lipid II into polymeric 
peptidoglycan. This reaction occurs at the outside of the cytoplasmic membrane and could 
likely be a target of oyster defensins. Therefore, purified recombinant PBP2-His6 was 
incubated with lipid II and Cg-Defh2 in different molar ratios. After 2 h incubation, the lipids 
were extracted with n-butanol/pyridine acetate (2:1) and separated by TLC (compare 
section 2.5.8). However, in presence of Cg-Defh2 lipid II could not be extracted, 
suggesting the formation of a complex which is insoluble in aqueous solution (Figure 9). 
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Figure 9 Inhibition of the PBP2-catalysed reaction by oyster defensins in vitro. Cg-Defh2 was 
incubated with lipid II and PBP2 in molar ratio of 1:1 and 1:2. In the presence of oyster 
defensin lipid II could not be extracted. 
 
Thus, the binding of oyster defensins was assayed by incubating the oyster defensins with 
lipid II at molar ratios ranging from 1:0.1 to 1:2 and directly spotting on the TLC plate 
(without extraction). With the addition of increasing amounts of oyster defensins, the free 
lipid II band disappeared from the TLC plate and became undetectable at a 1:1 molar ratio 
as shown in Figure 10 for Cg-Defh2. These data indicate that lipid II and oyster defensins 
bind to each other in a 1:1 stoichiometry.  
 
Moreover, surface plasmon resonance (SPR) experiments were performed to fully 
demonstrate the interaction on the binding of the three oyster defensin variants to lipid II 
and to obtain quantitative data of the binding process. Small unilamellar vesicles (SUV) of 
DOPC containing 0.8 mol% lipid II were prepared and immobilised on a SPR chip for 
interaction assays. The binding of oyster defensins was compared to that of nisin (positive 
control) and tachyplesin, an invertebrate LPS-binding antimicrobial peptide (negative 
control), at concentrations of 250 nM for each peptide. Although little to no binding of 
oyster defensins was observed on DOPC vesicles, a significant binding of the three 
defensin variants was observed on DOPC vesicles with 0.8 mol% lipid II. 
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Figure 10 The oyster defensin-lipid II complex. Lipid II was incubated in the presence of Cg-Defh2 at 
molar ratios ranging from 1:0.1 to 1:1. The stable complex remained at the application spot, 
whereas free lipid II migrated up the TLC plate. 
 
Overall, interaction kinetics were similar for defensins and nisin, although they differed by 
their association phase (Figure 11). The binding of oyster defensins appeared rather 
irreversible with no decay in the response units (RU) over time. As expected, tachyplesin 
did not bind to the DOPC vesicles containing 0.8 mol% lipid II, and even gave a negative 
signal most likely due to the membrane disruption properties of the peptide (Doherty et al., 
2006) (Figure 11). 
 
Figure 11 SPR analysis: Binding of oyster defensins to lipid II containing vesicles. The sensorgram 
depicts the interaction of oyster defensins, nisin (positive control) and tachyplesin (negative 
control) with immobilised DOPC vesicles containing 0.8 mol% lipid II. All peptides were 
added at 250 nM. The control sensorgrams (peptide interaction with immobilised DOPC 
vesicles) were subtracted from the data presented. 
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In two independent experiments, the three oyster defensins displayed higher binding to 
lipid II than nisin used as a positive control (2- to 4-fold higher RU). Interestingly, 
differential binding was also observed among the oyster defensin variants. Indeed, Cg-
Defh2 and Cg-Defm, which were also the most active variants (Table 8), gave similar 
association levels to DOPC vesicles with 0.8 mol% lipid II (Figure 11). Altogether, this 
shows that oyster defensins are strong ligands of lipid II and that differential binding 
occurs between variants. 
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3.2 Part 2: Insight into the antistaphylococcal mode of action of 
θ-defensins  
Theta-defensins are cyclic antimicrobial peptides composed of only 18 amino acids. They 
have been first isolated from the leukocytes and monocytes of rhesus macaques (RTDs, 
rhesus macque θ-defensin) (Tang et al., 1999; Tran et al., 2002) and subsequently found 
in many species of Old World monkeys (Garcia et al., 2008; Nguyen et al., 2003). They 
arose from a mutated α-defensin gene containing a premature stop codon in its defensin 
domain. During biogenesis a segment of 9 amino acids is excised from the defensin 
precursor and spliced head-to-tail to a similar or identical nonapeptide; the resulting 
homodimeric or heterodimeric products are stabilised by three disulphide bridges (Figure 
12; Tran et al., 2002). Rhesus macaques express three θ-defensin precursors which can 
pair to generate six different peptides (RTD-1 to RTD-6). Among these defensins, RTD-1 
is the most abundant (Tongaonkar et al., 2011). The peptides display a broad-spectrum 
activity against Gram-positive and Gram-negative bacteria, fungi and even enveloped 
viruses (Cole et al., 2002; Tang et al., 1999; Tran et al., 2002). Moreover, it has been 
demonstrated that the cyclic structure is crucial for their antimicrobial activity and confers 
salt resistance up to 150 mM NaCl (Tang et al., 1999). 
 
 
 
Figure 12 A: Amino acid sequence alignment, molecular weights and net charges (at pH 7) of 
heterodimeric RTD-1 and homodimeric RTD-2 and RTD-3; positively charged residues are 
marked in red. The peptide bond between G1 and R18 is indicated by lines (modified 
according to Tran et al., 2002).  
B: 3D structure of RTD-1 (Cole et al., 2002). 
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In this study, the antistaphylococcal action of θ-defensins was investigated using the 
heterodimeric RTD-1 and homodimeric RTD-2 (Figure 12). 
3.2.1 Antibacterial activity of θ-defensins against staphylococci 
The two θ-defensin variants, RTD-1 and RTD-2, were initially tested for their activities 
against different staphylococcal species in a standard broth microdilution assay. Both 
peptides exhibited potent antimicrobial activity and inhibited growth of the three test 
strains at concentrations ranging from 0.5 to 6 µg/ml (corresponding to 0.24 to 2.88 µM; 
Table 10).  
 
Table 10 Antimicrobial activity of RTDs against staphylococci in half-concentrated Mueller-Hinton 
broth. MIC values are expressed as the lowest concentration that caused visible growth 
inhibition. 
Strain RTD-1 RTD-2 
 µg/ml* µM µg/ml* µM 
S. aureus SG511-Berlin 6 2.88 4 1.91 
S. simulans 22 1.5 0.72 1.5 0.72 
S. carnosus TM300 0.75 0.36 0.5 0.24 
 
*Average values obtained from two or more independent experiments. 
3.2.2 Impact of RTDs on staphylococcal cell wall biosynthesis 
Recently, it has been shown that fungal (Schneider et al., 2010), invertebrate (section 3.1) 
and vertebrate defensins (de Leeuw et al., 2010; Sass et al., 2010) bind to and sequester 
the cell wall building block lipid II, thereby specifically inhibiting cell wall biosynthesis.  
In order to prove whether θ-defensins also interfere with membrane-bound steps of 
peptidoglycan biosynthesis, the accumulation of the final soluble cell wall precursor UDP-
MurNAc-pp was monitored in staphylococcal cells exposed to RTDs. S. simulans 22 and 
S. aureus SG511-Berlin were treated with defensins at 10x MIC and the cytoplasmic pool 
of UDP-linked peptidoglycan precursors was extracted and analysed by RP-HPLC 
(compare section 2.3.12). As it is shown in Figure 13, RTDs did not cause accumulation of 
UDP-MurNAc-pp in the cytoplasm compared to vancomycin-treated control cells. These 
data indicate that the antibiotic action of RTDs differ from that of the defensins mentioned 
above.  
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Figure 13 Intracellular accumulation of the final soluble cell wall precursor UDP-MurNAc-pp in 
S. simulans 22 (A, B) and S. aureus SG511-Berlin (C, D) exposed to θ-defensins. Cells 
were treated with 10x MIC vancomycin (positive control; A, C) or RTDs (B, D), incubated for 
30 min, and subsequently extracted with boiling water. The cytoplasmic pool was analysed 
by RP-HPLC. Intracellular accumulation of UDP-MurNAc-pp (arrow) was confirmed by mass 
spectrometry (data not shown). 
3.2.3 Impact of RTDs on macromolecular synthesis 
To investigate the effect of RTDs on intracellular bacterial biosynthetic reactions, the 
incorporation of 14C-thymidine, 3H-uridine and 14C-isoleucine into DNA, RNA and proteins 
of S. aureus SG511-Berlin was measured over a period of 2 h after peptide addition.  
Interestingly, all three biosynthesis pathways were simultaneously affected in a 
concentration-dependent manner (data at 1x MIC are shown in Figure 14), suggesting 
that in presence of RTDs cells are either unable to actively take up biosynthetic 
precursors or that macromolecular synthesis is generally impaired. Thus, the θ-defensin 
activity is distinct from the action of antibiotics that interfere specifically with one of the 
pathways. 
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Figure 14 Influence of RTDs on the macromolecular synthesis in S. aureus SG511-Berlin. The 
incorporation of 
14
C-thymidine into DNA (A), 
3
H-uridine into RNA (B) and L-
14
C-isoleucine 
into cellular proteins (C) of untreated and RTD-treated cells was measured over a period of 
2 h. Antibiotics that inhibit particularly one of the pathways were used as controls.  
3.2.4 Impact of RTDs on the membrane integrity 
Effects on the membrane integrity impair energy-dependent transport processes. Hence, 
permeabilisation of the bacterial membrane would explain the rapid and simultaneous 
inhibition of all biosynthetic reactions in the presence of RTDs. To assess the membrane 
impairment by θ-defensins, the potassium release of whole cells was monitored over a 
period of 5 min by growing S. simulans 22 in half-concentrated Mueller-Hinton broth and 
subsequently diluting the cells in choline buffer (compare section 2.3.9). 
Under these conditions, significant potassium efflux could not be observed in response to 
RTDs at 5x and 10x MIC (Figure 15 A). However, energisation of the cells by the addition 
of 10 mM glucose resulted in rapid concentration-dependent ion release after peptide 
treatment (Figure 15 B). Notably, RTD-1 had a stronger impact on the membrane integrity 
of S. simulans 22 than RTD-2. At concentrations corresponding to 10x MIC, RTD-1 
induced almost 90% ion leakage while RTD-2 led to 70% of potassium release after 5 min 
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incubation. In contrast, the activity of the pore-forming lantibiotic nisin - used here as a 
positive control - was independent of the presence of glucose (Figure 15). 
 
 
 
Figure 15 Impact on the membrane integrity of RTD-treated S. simulans 22 cells. Potassium efflux was 
monitored with a potassium-sensitive electrode in absence (A) and presence (B) of 10 mM 
glucose. The RTD-induced potassium release of energised cells could be blocked by the 
addition of 5 µM CCCP (carbonyl cyanide m-chlorophenylhydrazone; C). 
Ion leakage was expressed relative to the total amount of potassium released after addtion 
of 1 µM of the pore-forming lantibiotic nisin (100% efflux). RTDs were added at 5x and 10x 
MIC; controls were incubated without peptide. The arrows indicate the moment of peptide 
addition.  
 
These results indicate that the membrane activity of RTDs depends on the bacterial 
membrane potential. To further investigate this hypothesis, 5 µM of the ionophore CCCP 
(carbonyl cyanide m-chlorophenylhydrazone) were added to energised cells shortly after 
the peptides. CCCP uncouples the proton gradient across the cytoplasmic membrane 
leading to fast membrane depolarisation. Indeed, RTD-induced ion leakage was blocked 
immediately after CCCP addition (Figure 15 C).  
Moreover, the membrane potential of S. simulans 22 in choline buffer (used for the 
potassium efflux experiments) was estimated by the distribution of the lipophilic cation 
TPP+ inside and outside the cells. As expected, the membrane potential increased by 
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about 15-20 mV after incubation with 10 mM glucose (Figure 16). Thus, a high membrane 
potential - as it can be observed in presence of glucose - seems to be essential for the 
membrane-disrupting activity of RTDs. 
 
 
Figure 16 Membrane potential of S. simulans 22 suspension in choline buffer (300 mM choline 
chloride; 30 mM MES, 20 mM Tris; pH 6.5) used for potassium efflux experiments without an 
energy source. After 5 min incubation 10 mM glucose were added to the cells (arrow). 
 
Further, the membrane potential of S. aureus SG511-Berlin was monitored in half-
concentrated Mueller-Hinton broth which was routinely used for MIC determinations and 
mode of action studies. In absence of glucose, the peptides did not cause any change of 
the membrane potential when added at 10x MIC (Figure 17 A). In contrast, the addition of 
nisin induced a significant drop of the membrane potential of S. aureus SG511-Berlin 
(Figure 17 A). In presence of glucose, the membrane potential increased only slightly 
(approximately 10 mV; Figure 17 B). However, RTDs at 10x MIC caused a reduction of 
the membrane potential of about 15 mV which was completely restored after 20 min of 
treatment (Figure 17 B). 
Altogether, the degree of membrane impairment depends on the level of energisation and 
therefore on the membrane potential across the bacterial membrane. In cells with a 
certain membrane potential, θ-defensins disrupt the membrane barrier function causing a 
rapid efflux of small molecules such as potassium ions and a concomitant drop of the 
membrane potential. 
However, these data did not explain the complete cessation of all biosynthetic reactions 
as only a minor impact on the membrane integrity could be observed in medium lacking 
free glucose. Thus, the question was raised if the membrane impairment alone is 
sufficient for killing by RTDs or if additional activities are involved in the killing mechanism. 
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Figure 17 Membrane potential of S. aureus SG511-Berlin in half-concentrated Mueller-Hinton broth in 
absence (A) and presence (B) of 10 mM glucose. RTDs were added in concentrations 
corresponding to 10x MIC. The pore-forming peptide nisin (10x MIC) was used as a control. 
Arrows indicate the moment of peptide addition. 
3.2.5 Morphological changes of RTD-2 treated S. aureus cells 
Further, RTD-treated cells of S. aureus SG511-Berlin grown in half-concentrated Mueller-
Hinton broth, were inspected by transmission electron microscopy in order to obtain 
informations on potential additional activities. After 30 min treatment, additional 
membranous structures could be observed (Figure 18 A-C) in many cells, indicating the 
loss of cytoplasmic content. After 60 min exposure to RTD-2, cells showed degradation of 
the cell wall, particularly in the septum area between two daughter cells (Figure 18 D, E). 
Moreover, in some cells, the cell wall was completely peeled off (Figure 18 F). These 
morphological changes might indicate a premature activation of peptidoglycan lytic 
enzymes (referred to as autolysins) involved in cell separation.  
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Figure 18 Transmission electron microscopy of S. aureus SG511-Berlin treated with 10x MIC RTD-2. 
A: Untreated control cells. B, C: Cells treated for 30 min. Additional membranous structures 
could be observed. D, E, F: Cells treated for 60 min. Dividing cells showed degradation of 
the cell wall in the septum area between two daughter cells (D, E) or peeling of the cell wall 
(F). Scale bar: 0.2 µm.  
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Interestingly, RTD-treated cells resemble those exposed to the cationic antimicrobial 
peptide Pep5 produced by Staphylococcus epidermidis 5 (Bierbaum and Sahl, 1991). It 
has been demonstrated that Pep5 induces autolysis in S. simulans 22 (formerly  
S. cohnii 22) by releasing autolytic enzymes (Bierbaum and Sahl, 1985; Bierbaum and 
Sahl, 1987). In addition, Pep5 formes pores in energised cells leading to rapid efflux of 
small molecules (Sahl, 1985; Sahl and Brandis, 1983). Thus, it seems likely that the 
release of autolysins which hydrolyse the glycan chain and peptide bridges of murein also 
contributes to the killing by RTDs. 
3.2.6 Release of cell wall lytic enzymes by RTDs  
To provide further evidence that release of cell wall lytic enzymes is a relevant component 
of the antistaphylococcal activity of RTDs, the supernatant of RTD-treated cells was 
analysed for autolytic activity. Hence, S. aureus SG511-Berlin was incubated in the 
presence of RTDs at 10x MIC for 30 or 60 min, harvested and the concentrated 
supernatants were applied to a SDS-PAGE containing heat-inactivated M. luteus cells as 
substrate (compare section 2.5.3). Clear bands indicated the cell wall lytic activity of 
released enzymes. Cells exposed to Pep5 were included in the study and served as a 
positive control. 
Autolysins could be observed in all peptide treated samples, whereas hardly any activity 
was detectable in the untreated control (Figure 19 A). Interestingly, all detected bands 
represent different processed forms of the autolysin Atl as in an atl deletion mutant  
(S. aureus SA113 ∆atl; Figure 19 B) corresponding bands were missing after treatment 
with RTD-2 at 10x MIC. Atl is a bifunctional autolysin that plays a key role in separating 
cells after cell division and is highly conserved among staphylococci (Albrecht et al., 
2012). Proteolytic processing of the Atl precursor of S. aureus generates two catalytically 
active enzymes fused to repeat units, an amidase (AM, 62 kDa) and a glucosaminidase 
(GL, 51 kDa), that both bind to the septum site of dividing cells (Schlag et al., 2010; 
Yamada et al., 1996). Besides the AM and GL bands, three additional bands with 
molecular masses of 138 kDa, 113 kDa and 87 kDa could be detected. The 138 kDa band 
corresponded to the full length protein (Pro-Atl). The 113 kDa and 87 kDa bands 
presumambly represented the unprocessed amidase and glucosaminidase domain after 
proteolytic cleavage of the signal and propeptide (Atl) and the amidase with the 
propeptide (PP-AM), respectively (according to Schlag et al., 2010).  
Remarkable differences could be revealed between RTD-1 and RTD-2 treated cells. A 
stronger enzyme activity was detected in the supernatant of cells exposed to RTD-2 - 
particular after 60 min treatment (Figure 19).  
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Recently, it has been demonstrated that the Atl amidase is directed to the septal region by 
its repeat domains where it binds to lipoteichoic acid (LTA) (Zoll et al., 2012). 
Consequently, the release of Atl by Pep5 as well as RTDs suggests that these cationic 
peptides bind to the polyanionic LTA, thereby replacing the autolytic enzymes and 
inducing autolysis. 
 
 
 
Figure 19 Detection of cell wall lytic enzymes in the supernatant of RTD-treated cells. 
A: S. aureus SG511-Berlin was exposed to 10x MIC of RTDs or Pep5 for 30 and 60 min. 
Equal amounts of the concentrated culture supernatant (containing autolysins released from 
the cell surface) were separated on a 12% SDS-PAGE containing heat-inactivated M. luteus 
cells as substrate. Clear bands represent cell lysis zones.  
B: S. aureus SA113 ∆atl treated for 60 min with 10x MIC RTD-2.  
All bands represent differently processed Atl forms as in the atl deletion mutant the 
corresponding autolysis bands were missing (B). 
Pro-Atl: Atl with full-length propeptide, Atl: amidase and glucosaminidase, PP-AM: amidase 
with propeptide, AM: amidase, GL: glucosaminidase. 
 
Consistent with the release of the autolysin Atl by RTDs, θ-defensin-mediated killing was 
diminished in S. aureus SA113 ∆atl. Killing kinetics of the atl deletion mutant and its wild-
type strain showed that the mutant was significantly more resistant towards the action of 
RTD-2 (Figure 20). The number of colony forming units (CFU) of the WT was reduced by 
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several logs after addition of the peptide, whereas the atl deletion mutant was only slightly 
affected by RTD-2 even at 80 µg/ml (Figure 20).  
 
Figure 20 Killing kinetic of S. aureus SA113 (WT) and its atl deletion mutant (∆atl) in half-concentrated 
Mueller-Hinton broth and presence of 40 and 80 µg/ml RTD-2 over a period of 4 h. 
 
However, no differences of the MIC values between the wildtype and the mutant could be 
detected after 24 h incubation (Table 11) as the bacteria which have not been killed by 
RTDs were able to regrow during this long incubation time.  
Since LTA serves as an anchor molecule for Atl (Zoll et al., 2012), two strains with an 
altered LTA content were included in the study. S. aureus SA113 ∆ypfP has a 87% 
reduced LTA content compared to the wild-type strain and the remaining LTA are directly 
linked to diacylglycerol (DAG) instead of diglucosyl-DAG (Glc2-DAG) (Fedtke et al., 2007). 
Moreover, the recently described LTA-deficient suppressor strain S. aureus SEJ1 ∆ltaS 
(4S5) was tested for its susceptibility towards RTDs and Pep5. Unexpectedly, both strains 
were more susceptible towards Pep5, while only S. aureus SEJ1 ∆ltaS (4S5) showed a 
lower MIC of RTDs compared to the parental strain (Table 11).  
Table 11 Antibacterial activity of RTDs and Pep5 (µg/ml)* against S. aureus mutants affected in 
autolysis or LTA synthesis in 10% Mueller-Hinton broth. MIC values are expressed as the 
lowest concentration that caused visible growth inhibition. 
Strain RTD-1 RTD-2 Pep5 
S. aureus SA113 16 8 4 
S. aureus SA113 ∆atl 16 8 4 
S. aureus SA113 ∆ypfP 16 16 1 
S. aureus SEJ1 >32 32 4 
S. aureus SEJ1 ∆ltaS (4S5) 4 2 0.125 
 
*Average values obtained from two or more independent experiments. 
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3.2.7 Antagonisation of antibacterial activity of θ-defensins  
LTA serves as a receptor for the repeat domains of AM and GL at the septum (Zoll et al., 
2012) and it was proposed that RTDs and Pep5 bind to LTA, thereby releasing autolytic 
enzymes. To further confirm that the peptides interact with LTA, an antagonisation assay 
was performed. For this, isolated LTA was added as potential antagonist to a liquid growth 
inhibition assay in a 1:1, 1:2 or 1:4 molar ratio with respect to the peptide. Indeed, addition 
of LTA inhibited the antimicrobial activity of RTDs when used at 1:4 molar ratio, but did not 
antagonise the antibiotic action of Pep5 (Table 12). Earlier studies reported an inhibition of 
Pep5-induced lysis by LTA at a 10-fold molar excess (Bierbaum and Sahl, 1985).  
 
Table 12 Antagonisation of antimicrobial activity of θ-defensins and Pep5 against S. aureus SG511-
Berlin by LTA. The following symbols are used: + for antagonisation; - for normal 
antimicrobial activity. 
Molar ratio 
peptide:LTA 
RTD-1 RTD-2 Pep5 
1:1 - - - 
1:2 - - - 
1:4 + + - 
 
3.2.8 Release of carboxyfluorescein from LTA-containing liposomes 
As it was proven that θ-defensins and Pep5 interact with membrane-bound teichoic acids, 
it was further investigated whether this interaction also facilitates the pore-formation 
process. For example, nisin and related peptides use lipid II as docking molecule to 
subsequently form pores in the membrane of susceptible strains.  
Therefore, carboxyfluorescein-loaded liposomes were made of DOPC and 0.5 mol% 
purified LTA and the efflux of the fluorescent dye was monitored after addition of 1 µM of 
each peptide. Pure DOPC vesicles were used as a control. As shown in Figure 21, only 
minor marker release was observed with pure DOPC vesicles and DOPC doped with LTA. 
Thus, LTA does not seem to be involved in the membrane-disrupting activity of RTDs and 
Pep5. 
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Figure 21 Carboxyfluorescein (CF) release from liposomes made of DOPC and 0.5 mol% LTA isolated 
from S. aureus SG511-Berlin. RTDs (A) and Pep5 (B) were added at 1 µM. Marker release 
was expressed relative to the amount of CF released after addition of Triton X-100 (100% 
efflux). Pure DOPC vesicles were used as a control. 
3.2.9 Susceptibility testing of a PepI producing strain 
The Pep5 producer strain S. epidermidis 5 protects itself from the lethal action of its own 
peptide by the immunity peptide PepI. This peptide consists of 69 amino acids forming a 
hydrophobic N-terminal domain and a hydrophilic C-terminus. It has been demonstrated 
that PepI is translocated across the membrane and localises in the outer leaflet of the 
cytoplasmic membrane where it probably shields the Pep5 target (Hoffmann et al., 2004). 
However, the interaction partner of PepI is still unknown.  
The results described above indicate that RTDs may act in a similar way as the lantibiotic 
Pep5. In order to examine if PepI also confers resistance towards RTDs, a MIC 
determination with S. carnosus TM300 carrying pepI under a xylose-inducible promotor 
was performed. As expected, PepI expression resulted in significant Pep5 insensitivity 
(MIC increased by the factor 32), while the RTD sensitivity decreased by the factor 2 to 
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2.5 (Table 13), indicating that PepI can in part contribute to θ-defensin resistance. These 
results provide a further hint that Pep5 and RTDs may have a similar mechanism of 
action. 
 
Table 13 MIC values (µg/ml)* of S. carnosus TM300 expressing pepI under a xylose-inducible 
promotor in half-concentrated Mueller-Hinton broth. PepI synthesis was induced by addition 
of 1% xylose. MIC values are expressed as the lowest concentration that caused visible 
growth inhibition. 
 RTD-1 RTD-2 Pep5 
S. carnosus TM300 pAH-PepI    
- xylose 1 0.75 0.06 
+ xylose 2 2 2 
 
*Average values obtained from two or more independent experiments. 
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3.3 Part 3: Insight into the Gram-negative mode of action of defensins 
The epithelial human β-defensin 3 (hBD3) is a highly cationic peptide (net charge +11) 
that forms dimers in solution (Schibli et al., 2002) and retains antimicrobial activity at 
physiological salt concentrations (Boniotto et al., 2003; Harder et al., 2001). Harder et al., 
(2001) first described hBD3 and observed cell wall perforations of hBD3 treated 
staphylococcal cells, indicating interference of hBD3 with peptidoglycan biosynthesis or 
localised induction of lytic enzymes. Later studies confirmed that hBD3 bind to the cell 
wall precursor lipid II in a 1:1 molar ratio (Sass et al., 2010). Further, hBD3 causes a 
small, but significant reduction of the membrane potential and the transcriptional response 
pattern of hBD3-treated staphylococci is in part similar to that of cells exposed to 
membrane-active α-helical HDPs, suggesting that hBD3 additionally affects energy 
generation and membrane transport processes. Thus, killing of S. aureus by hBD3 is the 
result of pleiotropic effects on membrane bound processes on top of specific cell wall 
inhibition caused by lipid II sequestration (Sass et al., 2008; Sass et al., 2010). 
In addition, the peptide displays activity against Gram-negative bacteria and fungi (Harder 
et al., 2001; Garcia et al., 2001). It has been proposed – after analysis of chimeric and 
shortened hBD3 peptides – that the antibiotic action against S. aureus is linked to the N-
terminus whereas the highly charged C-terminal part plays a predominant role in the 
activity against E. coli (Hoover et al., 2003; Jung et al., 2011). Here, hBD3 was analysed 
for its activity against Gram-negative bacteria by studying its interaction with the cell 
envelope of E. coli.  
 
 
Figure 22 A: Amino acid sequence, molecular weight and net charge of hBD3 (at pH 7). Residues with 
a positive charge are marked in red, negatively charged residues are marked in blue. 
B: 3D structure of hBD3 (Schibli et al., 2002). 
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3.3.1 Antibacterial activity of hBD3 against E. coli 
Initially, the antimicrobial activity of hBD3 against different E. coli strains was determined 
in 10% Mueller-Hinton broth which was used as medium in all further experiments. Under 
this condition, the defensin inhibited the growth of all three test strains at a concentration 
of 1 µM (Table 14). 
 
Table 14 Antibacterial activity of hBD3 against different E. coli strains in 10% Mueller-Hinton broth. 
MIC values (µM)* are expressed as the lowest concentration that caused visible growth 
inhibition. 
*Average values obtained from two or more independent experiments. 
3.3.2 Growth kinetic measurements in presence of hBD3 
Growth kinetic measurements of E. coli BW25113 exposed to hBD3 and various 
antibiotics with known cellular targets (at 5x MIC) were carried out in order to obtain 
information on its mode of action against Gram-negative bacteria. Interestingly, the hBD3 
behaviour was neither similar to the rapid membranolytic action of polymyxin B nor to the 
activity of cell wall inhibitors (ampicillin, penicillin G; Figure 23) which cause killing over 
the course of one bacterial generation.  
 
 
Figure 23 Growth kinetic measurements of E. coli BW25113 in presence of hBD3 and various 
antibiotics with known cellular targets at 5x MIC. 
Strain MIC (µM) 
E. coli ATCC 25992 1 
E. coli BW25113 1 
E. coli ML-35pYC 1 
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In contrast, hBD3 induced cellular lysis in S. aureus SG511-Berlin which is consistent with 
the reported inhibition of cell wall biosynthesis (data not shown). 
These results suggest that the activity of hBD3 against Gram-negative bacteria differs 
from its mode of action against Gram-positive bacteria and that additional targets might be 
involved in killing.  
3.3.3 Permeabilisation of E. coli outer and inner membrane 
The ability of hBD3 to permeabilise both the outer and the cytoplasmic membrane of  
E. coli ML-35pYC was studied by following the hydrolysis of two extracellular chromogenic 
reporter molecules. Outer membrane disruption was indicated by cleavage of the 
cephalosporin CENTATM by the periplasmic β-lactamase of this strain (Figure 24 A), 
whereas inner membrane permeabilisation was measured by the rate of ONPG (o-
nitrophenyl-β-D-galactopyranoside) hydrolysis by the cytoplasmic β-galactosidase (Figure 
24 B). Polymyxin B – which is known to induce pore-formation in both membranes – was 
used as a positive control. 
A rapid hydrolysis of CENTATM was observed in presence of polymyxin B and hBD3, 
indicating efficient outer membrane disruption. At 5x MIC, hBD3 achieved similar levels of 
membrane permeabilisation as polymyxin B (Figure 24 A). 
In contrast, inner membrane permeabilisation was significantly slower in cells exposed to 
hBD3 in comparison to those treated with polymyxin B. Interestingly, no further ONPG 
hydrolysis could be measured after 60 min treatment with 5x MIC of hBD3, although the 
maximum reaction rate had not been reached (Figure 24 B).  
 
 
Figure 24 Inner and outer membrane permeabilisation of E. coli ML35-pYC. A: Outer membrane 
permeabilisation was assessed by the hydrolysis of the extracellular chromogenic 
cephalosporin CENTA
TM
 by the periplasmic β-lactamase of this strain. B: Inner membrane 
permeabilisation was determined by following the cleavage of the extracellular substrate 
ONPG by the constitutively expressed β-galactosidase of E. coli ML35-pYC. The pore-
forming antibiotic polymyxin B was used as a control.  
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3.3.4 Morphological changes of hBD3 treated E. coli cells 
To further investigate the effect of hBD3 on E. coli BW25113, the morphology of treated cells was examined by transmission electron 
microscopy. Blebbing of the outer membrane was noted within 30 min of exposure (Figure 25 B, C) and became more frequent after 60 
min (Figure 25 D, E). This effect is indicative of LPS released from the cell surface. Moreover, densed material could be monitored on the 
external face of the outer membrane of some cells (Figure 25 B, E). 
Consistent with the previous described results (Figure 23), the interaction of hBD3 with the membranes of E. coli did not cause a 
significant loss of cytoplasmic content that would indicate generalised cell rupture. 
 
 
Figure 25 Transmission electron microscopy of E.coli BW25113 treated with 10x MIC hBD3. A: Untreated control cells. B, C: Cells treated for 30 min. D, E: 
Cells treated for 60 min. Evaginations of the outer membrane could be observed. Scale bar: 0.4 µm. 
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3.3.5 Activity of hBD3 against E. coli strains with different LPS structures 
As the initial interaction of hBD3 with the outer membrane seems to be crucial for its 
activity, the susceptibility of E. coli strains with different LPS structures was investigated 
by determining the IC50 values (Figure 26 B). Among these strains, E. coli ATCC 25992 
with full-length LPS and E. coli BW25113 lacking the O antigen were significantly more 
susceptible towards hBD3 than the tested mutants which differ in their LPS core region 
(Figure 26). 
 
 
 
Figure 26 A: LPS structures of different E. coli strains tested. ATCC 25992: full-length LPS, BW25113: 
lacks the O antigen, ∆waaG: lacks the outer core region, ∆waaY: lacks one phosphate group 
in the inner core region, ∆waaP: deficient in core phosphate. 
B: IC50 values of hBD3 (µM) against the E. coli strains described above.  
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The kinases WaaP and WaaY are involved in phosphorylation of heptose residues in the 
inner core region of LPS. Thus, a mutation in one of the corresponding genes decreases 
the net negative charge of the LPS molecules, and thereby lowering the affinity towards 
cationic peptides. Consistently, the ∆waaP and ∆waaY deletion mutants were more 
resistant towards hBD3. Interestingly, E. coli ∆waaG lacking the outer core region showed 
also a higher hBD3 resistance compared to the wild-type strain (E. coli BW25113). 
Hence, the susceptibility towards hBD3 depends on the composition of LPS, and not only 
the phosphate residues, but also the sugars of the outer core region seem to be involved 
in the interaction. 
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4 Discussion 
The antibacterial mode of action of defensins was long thought to result from electrostatic 
interaction between the cationic peptides and the negatively charged microbial 
membranes, followed by pore-formation or unspecific membrane permeabilisation. 
Previous studies and the results of this thesis have clearly demonstrated that the action of 
defensins can be much more targeted and that specific lipid-bound molecules of the 
microbial cell envelope are involved in killing. 
4.1 Part 1: The central cell wall building block lipid II as target for 
defensins 
Here, the mode of action of antibacterial invertebrate defensins was studied with three 
defensin variants (Cg-Defm, Cg-Defh1, Cg-Defh2) isolated from the oyster C. gigas. 
Results showed that oyster defensins kill S. aureus through binding to lipid II, thus 
inhibiting peptidoglycan biosynthesis. To date, only invertebrate defensins with antifungal 
activity had been characterised in terms of cellular targets (Thevissen et al., 2004).  
The biosynthesis of bacterial cell wall peptidoglycan is a multistep process involving 
reactions in the cytoplasm and both sides of the cytoplasmic membrane (for details see 
Figure 27). It is a prominent target for many antibacterial compounds from different 
chemical classes, including glycopeptides, lipopeptides and lantibiotics. Particularly, the 
building block lipid II is trapped by many compounds when presented on the outer face of 
the bacterial cytoplasmic membrane. For example, the clinically-used glycopeptides such 
as vancomycin bind to the D-Ala-D-Ala terminus of the lipid II side chain, thereby causing 
sequestration of the precursor from PBPs and subsequently blocking its further 
incorporation into the cell wall (Schneider and Sahl, 2010). Moreover, the lantibiotic nisin 
(which was used as a positive control during this study) and related peptides combine  
lipid II targeting with membrane permeabilisation (Wiedemann et al., 2001). Very recently, 
lipid II binding has also been described for one fungal defensin named plectasin 
(Schneider et al., 2010) and two mammalian defensins – representatives of the α- and β-
defensin family – namely HNP-1 and hBD3 (de Leeuw et al., 2010; Sass et al., 2010).  
The oyster defensins displayed potent activity against several Gram-positive bacteria, 
including staphylococci which were chosen for further mode of action studies (Table 8). 
Incubation of S. simulans 22 with oyster defensins resulted in the accumulation of the last 
soluble cell wall precursor UDP-MurNAc-pp in the cytoplasm, comparable to classical 
inhibitors of the membrane-bound steps of cell wall biosynthesis (Figure 8). Moreover, 
lipid II antagonised the oyster defensin activity against S. aureus, whereas C55-P (which 
serves as a lipid carrier in lipid II) as well as UDP-MurNAc-pp and UDP-GlcNAc (the 
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activated cell wall sugars forming the disaccharide moiety of lipid II) did not (Table 9). The 
antagonisation of the oyster defensins antibacterial activity by lipid II occurred at a 1:1 
molar ratio (Table 9), as also observed for plectasin (Schneider et al., 2010) and for hBD3. 
However, the latter one was also antagonised by C55-P and negatively charged 
phospholipids when added in up to a 5-fold molar excess (Sass et al., 2010). The 1:1 
stoichiometry was also confirmed here by TLC, as indicated by the absence of free lipid II 
on the plate at this molar ratio (Figure 10). 
Altogether, this result suggests that targeting of lipid II by oyster defensins requires lipid II-
specific molecular determinants such as the disaccharide-pyrophosphate moiety, which is 
targeted by the lantibiotics. NMR-based modelling of the plectasin-lipid II complex 
revealed that the defensin interacts with the pyrophosphate moiety of lipid II via hydrogen 
bonding (involving residues F2, G3, C4 and C37), whereas the hydrophobic part of the 
peptide is located on the membrane surface (Figure 4) (Schneider et al., 2010). Indeed, 
the three-dimensional structure of the oyster defensins is similar to that of plectasin 
although they possess a fourth disulphide bridge. Further, the amino acid residues 
involved in lipid II binding of plectasin are also present in the Cg-Defs (F2, G3, C4, C34) 
and other antibacterial invertebrate defensins, suggesting a conserved interaction motif. 
Consequently, it can be proposed that those defensins carrying a CSαβ motif and 
displaying exclusively antibacterial activity could have a similar mechanism of action, 
which involves lipid II-binding and subsequent inhibition of cell wall biosynthesis. This is 
consistent with their preferential activity against Gram-positive bacteria (Bulet and 
Stocklin, 2005; Mygind et al., 2005; Froy and Gurevitz, 2003; Otvos, 2000). In addition, 
antifungal invertebrate defensins with a CSαβ fold such as heliomicin do not contain the 
amino acids of the lipid II binding motif. Consistently, it has been shown that heliomicin 
does not bind to lipid II (Schneider et al., 2010) and lacks antibacterial activity (Lamberty 
et al., 1999), thus reinforcing the hypothesis that lipid II-binding is an essential 
determinant of invertebrate defensin antibacterial activity.  
In contrast, antifungal invertebrate and plant defensins interact with specific sphingolipids, 
thereby leading to fungal cell death (compare section 1.3) (Aerts et al., 2009; Thevissen et 
al., 2004). Thus, evidence is increasing that invertebrate defensins, and more generally 
CSαβ-type defensins, are rather specific inhibitors of microbial biosynthesis or signalling 
pathways than mere membrane active agents.  
The binding of oyster defensins to lipid II was shown to be very strong as determined here 
by SPR. The oyster defensins bound to DOPC vesicles containing 0.8 mol% lipid II in an 
almost irreversible manner, as indicated by the absence of decay in the RU values during 
the dissociation step (Figure 11). All defensin variants (Cg-Defm, Cg-Defh1, and Cg-
Defh2) gave higher binding responses than nisin. Among the oyster defensins, Cg-Defh2 
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showed the highest affinity for lipid II (Figure 11). This correlates with its antimicrobial 
activity as Cg-Defh2 exhibited 2- to 4-fold lower MIC values than Cg-Defh1 and Cg-Defm 
(Table 8).  
Interestingly, it has been demonstrated that all three defensins belong to distinct groups 
which evolved through gene duplication and subsequent functional divergence (Schmitt et 
al., 2010). This study supports the hypothesis that strong selective pressures have 
directed oyster defensins towards the design of new variants with higher potency. Cg-
Defm and Cg-Defh2, the more active forms, exhibit a positively charged residue at 
position 16 (K and R, respectively; Figure 6) instead of an uncharged glutamine in Cg-
Defh1. As these residues are exposed on the surface of the peptide (Gueguen et al., 
2006) they might be involved in binding to lipid II, thus explaining the different affinity of 
the three variants for the peptidoglycan precursor. Similarly, a lysine on the surface of 
plectasin is crucial for the antibacterial activity, probably by promoting a better binding to 
the cell wall and membrane of bacteria (Schneider et al., 2010). Therefore, variations in 
oyster defensin potency could depend on charge distribution driven by sites under 
diversifying selection.  
The binding of oyster defensins to lipid II likely occurs at the outer leaflet of the 
cytoplasmic membrane. At lethal concentrations (10x MIC), oyster defensins did not 
compromise the cytoplasmic membrane of S. aureus (Figure 7). For this reason, they 
should have no access to the inner leaflet of the cytoplasmic membrane where lipid II is 
synthesised and decorated with a pentaglycine interpeptide bridge before it is translocated 
across the cytoplasmic membrane. Consequently, the mechanism of action of oyster 
defensins might involve binding and sequestration of extracellular lipid II, thereby blocking 
its polymerisation into mature peptidoglycan (Figure 27). 
Consistent with the use of lipid II as a molecular target, oyster defensins have been shown 
to be highly active against Gram-positive bacteria (in the nanomolar range) and barely 
active (≥ 20 μM) against Gram-negative bacteria (Table 8). Indeed, in Gram-negative 
bacteria the peptidoglycan is protected by the outer membrane preventing access of 
oyster defensins to the periplasmic space in the absence of membrane damage. As a 
consequence, the different susceptibility of Gram-positive and Gram-negative bacteria to 
oyster defensins probably results from a differential access to lipid II. The cell wall building 
block is readily accessible in Gram-positive bacteria, but requires outer membrane 
damage to become accessible in Gram-negative bacteria. Such outer membrane damage 
can be induced by high concentrations of oyster defensins, as observed above 10 μM 
against the Gram-negative oyster pathogen V. splendidus LGP32 (Duperthuy et al., 
2010). Consistently, Cg-Defs have a synergistic effect with Cg-Prps (proline rich HDPs of  
C. gigas) and Cg-BPI (bactericidal/permeability-increasing protein of C. gigas) against 
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Gram-negative bacteria, probably by combining membrane-disrupting activities with 
specific lipid II binding (Gueguen et al., 2009; Schmitt et al., 2012a). 
 
 
 
Figure 27 Inhibition of cell wall biosynthesis by defensins. Various defensins bind to lipid II, thereby 
causing sequestration of the precursor from PBPs and subsequently blocking its further 
incorporation into the cell wall. 
 
Lipid II targeting has also been reported for the mammalian α-defensin HNP-1 (de Leeuw 
et al., 2010) and human β-defensin 3 (Sass et al., 2010). However, unlike invertebrate 
defensins, mammalian defensins are active against both Gram-positive and Gram-
negative bacteria (Harder et al., 2007; Schneider et al., 2005). If both mammalian and 
invertebrate antibacterial defensins have the same target, what makes the invertebrate 
defensins so selective towards Gram-positive bacteria? One hypothesis is that unlike 
invertebrate antibacterial defensins, which require lipid II to be readily accessible, 
mammalian defensins could use their membrane-disrupting properties (Boniotto et al., 
2003; Lehrer et al., 1989) to gain access to lipid II in Gram-negative bacteria. Indeed, the 
membrane-disrupting activity of invertebrate defensins appears much weaker than that of 
mammalian defensins. This was shown for oyster defensins (Figure 7), and earlier for the 
D. melanogaster defensin A, which required very high defensin/bacterial cell ratio (105:1) 
to induce potassium efflux in M. luteus (Cociancich et al., 1993). Permeabilisation of the 
outer membrane by cationic peptides is proposed to occur by self-promoted uptake. The 
initial step in this process is the interaction of the peptides with the negatively charged 
LPS, thereby leading to displacement of divalent cations that crossbridge adjacent LPS 
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molecules (Hancock, 1997). Subsequently, outer membrane disruption might depend on 
the cationic net charge of the peptides. For example, hBD3 displays a net charge of +11 
while plectasin or the oyster defensins carrying a net charge of +1 to +3. Moreover, many 
vertebrate defensins form stable dimers or oligomers in solution, which results in an even 
higher charge density that could likely be important for their membrane activity (Boniotto 
et al., 2003; Schibli et al., 2002).  
However, it has been demonstrated that the binding constant of plectasin to  
lipid II (1.8 x 10-7 M) (Schneider et al., 2010) is about one order of magnitude higher 
compared to the α-defensin HNP-1 (2.19 x 10-6 M) (de Leeuw et al., 2010). These findings 
indicate that the specificity of lipid II binding correlates to some extent with the 
antimicrobial spectrum. Possibly, peptides such as HNP-1 and hBD3 displaying lower 
affinity towards the cell wall precursor and a broader activity spectrum, may thereby retain 
affinity for additional targets to kill other microbes, e.g. Gram-negative bacteria (compare 
section 4.3). 
As Cg-defs are only active against Gram-positive bacteria, the oyster C. gigas has to 
produce additional HDPs to control pathogens such as Gram-negative bacteria. Indeed, 
three representatives of the big defensin family have been recently isolated from this 
invertebrate (Cg-BigDef 1-3) (Rosa et al., 2011) which were reported to be active against 
both Gram-positive and Gram-negative bacteria (compare section 1.2). Moreover, two Cg-
BPIs (bactericidal/permeability-increasing proteins) have been identified displaying 
exclusively Gram-negative activity (Gonzalez et al., 2007b; Zhang et al., 2011) as well as 
two proline-rich peptides (Cg-Prps) exhibiting only weak antimicrobial action (Gueguen et 
al., 2009; Schmitt et al., 2012a). As described above, these peptides can act 
synergistically, thereby increasing their potency as well as their activity spectrum (Schmitt 
et al., 2012a). 
However, this raises the question which selective pressure has driven the development of 
defensins from peptides with a highly specific target to peptides with a reduced affinity and 
a broad-spectrum activity (as they can be found in vertebrates)? In this context, it is worth 
to recall that vertebrate defensins also display a diverse range of immunomodulatory 
functions and even bridge the innate and adaptive immune response, thereby contributing 
to bacterial clearance (section 1.4). In contrast, little is known about such functions in 
invertebrates. It has been shown that some invertebrate defensins neutralise LPS or 
induce signal transduction or gene transcription in mouse models (Hancock et al., 2006), 
but nothing has been reported about the immunomodulatory activities in the invertebrate 
host itself. 
Nevertheless, it could be hypothesised that during the process of gaining new functions in 
terms of immunomodulation, defensins may have reduced their direct antimicrobial activity 
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and/or target specificity. This is consistent with the fact that some defensins completely 
lack direct antibiotic activities such as the human enteric α-defensin HD6. It has been 
recently found that HD6 entraps bacteria in peptide nanosets without affecting their 
viability (Chu et al., 2012; Ouellette and Selsted, 2012). 
4.2 Part 2: Induction of autolysis as mode of action of defensins 
Apparently, θ-defensins do not only differ structurally from all other defensins, they also 
seem to act by a different mechanism. In this study, it was demonstrated that RTDs 
(rhesus macaque θ-defensins) do not interfere with peptidoglycan biosynthesis (Figure 
13), but rather induce bacterial lysis in staphylococci by interaction with the bacterial 
membrane and/or release of autolytic enzymes (Figure 28).  
The membrane permeabilisation by RTDs depended strongly on the energisation of the 
membrane as revealed by potassium efflux experiments and membrane potential 
measurements (section 3.2.4). Similar observations have been described for the lantibiotic 
Pep5, a cationic peptide of bacterial origin. Pep5 also forms transient pores in energised 
membranes leading to rapid efflux of low molecular weight substances from the cytoplasm 
(Poppinga, 2007; Sahl, 1985; Sahl and Brandis, 1983).  
Different models have been elaborated to describe the interaction of cationic peptides with 
the bacterial membrane. The “wedge model” was suggested to explain the pore formation 
process in presence of a high transmembrane potential. In this model, the amphiphilic 
molecules adhere to the anionic lipids on the membrane surface; in response to the 
electrical potential the lipid-associated peptides change the orientation (to a wegde-
shape), thereby moving through the membrane to form a water-filled pore (Driessen et al., 
1995; Sahl and Bierbaum, 1998). Unlike other HDPs, the highly flexible RTD structure 
lacks the typical amphiphilic character, even though it exhibits a certain clustering of 
positive charges (Trabi et al., 2001). Consequently, the peptides do not have a 
hydrophobic patch which allows insertion into the bilayer. In contrast, reports on the 
biophysical behaviour of RTD-1 in model membranes showed that the peptide induces 
membrane thinning when it binds to the membrane surface (Weiss et al., 2002) and that 
RTD molecules probably aggregate in the membrane (Buffy et al., 2004).  
For Pep5, it has been hypothesised that it uses a docking molecule for binding to the 
cytoplasmic membrane and subsequent pore-formation (Brotz et al., 1998; Hoffmann et 
al., 2004). Earlier studies have demonstrated that Pep5 does not form a complex with  
lipid II (Brotz et al., 1998) in contrast to nisin which uses the cell wall precursor as an 
anchor for defined pore-formation (Wiedemann et al., 2001). Since Pep5 and RTDs bind 
to the membrane-anchored LTA (Table 12) (Bierbaum and Sahl, 1985; Bierbaum and 
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Sahl, 1987) thereby releasing autolytic enzymes, it was investigated whether this 
interaction also facilitates pore-formation. Under the tested conditions, neither Pep5 nor 
RTDs caused leakage of small vesicles containing purified LTA (Figure 21). This suggests 
that the membrane-disrupting activity of these peptides might depend on the membrane 
potential only. Voltage-dependent channel formation in model membranes has also been 
described for the α-defensin HNP-1 (Kagan et al., 1990). 
The membrane perturbation may contribute, but not solely account for killing of 
staphylococcal cells by RTDs. Further, it could be demonstrated that these peptides 
activate peptidoglycan hydrolases (also referred to as autolysins; Figure 19). These 
enzymes are responsible for splitting the septum during cell division and enable 
incorporation of newly synthesised cell wall precursors during cell growth (Vollmer et al., 
2008). The premature and uncontrolled activity of autolysins can cause cell lysis and 
subsequently cell death as observed in presence of θ-defensins. Zymogram analysis 
revealed that RTDs release differently processed forms of Atl, the most prominent 
autolysin of staphylococci (Figure 19). Consistently, an atl deletion mutant was 
significantly more resistant towards the activity of RTDs (Figure 20). Atl can also be 
activated by high salt concentrations (Heilmann et al., 1997) and the lantibiotics nisin and 
Pep5 (Bierbaum and Sahl, 1985; Bierbaum and Sahl, 1987). This hydrolase is 
synthesised as a pre-pro-peptide that is cleaved into two enzymatically active domains – 
an amidase (AM; that cleaves the amide bond between MurNAc and L-alanine) and a 
glucosaminidase (GL; that cleaves the β-1,4-gycosidic bond between GlcNAc and 
adjacent monosaccharides) – by an as yet uncharacterised mechanism (Heilmann et al., 
1997; Schlag et al., 2010). Both enzymes localise at the cross wall of dividing cells 
(Yamada et al., 1996). Indeed, electron micrographs revealed that degradation of 
peptidoglycan of RTD-2 treated cells occurred particular at the septum between two 
daughter cells (Figure 18 D, E).  
The AM and GL are each fused to repeat units that are responsible for targeting the 
enzymes to the cross wall (Baba and Schneewind, 1998; Komatsuzawa et al., 1997). It 
has been reported that in S. aureus wall teichoic acid (WTA) – present in the old cell wall 
– acts as a repellent for the repeats, thereby directing the enzymes to the septum, where 
they bind to and are controlled by LTA (Schlag et al., 2010; Zoll et al., 2012). This 
suggests that cationic molecules such as RTDs and Pep5 bind to the polyanionic LTA, 
thereby liberate the enzymes such that they can degrade the cell wall in an uncontrolled 
manner. An antagonisation assay confirmed that LTA completely suppresses the 
antimicrobial activity of RTDs when added in a 4-fold molar excess in respect to the 
peptide (Table 12). In contrast, higher LTA concentrations (10-fold molar excess) are 
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necessary to antagonise the antibiotic action of Pep5 (Bierbaum and Sahl, 1985) which is 
consistent with the data obtained here (Table 12).  
The number of positive charges of a given peptide might be of particular relevance for the 
interaction with LTA and thereby for the release of autolysins (Bierbaum and Sahl, 1987). 
A higher autolysin activity could be detected in the supernatant of cells exposed to RTD-2 
(net charge +6) and Pep5 (net charge +7; which served as a positive control) compared to 
cells treated with RTD-1 (net charge +5).  
Notably, the unprocessed Atl forms could also be detected in the supernatant of treated  
S. aureus cells (Figure 19), indicating that the processing of the enzyme occurs at the 
septum when bound to LTA.  
Moreover, two mutants with a reduced LTA content (S. aureus SA113 ∆ypfP and  
S. aureus SEJ ∆ltaS (4S5)) were tested for their susceptibility towards RTDs and Pep5. 
Consistently, these strains have either a lowered autolysis rate (Fedtke et al., 2007) or a 
reduced amount of hydrolytic enzymes bound to the cell envelope (Corrigan et al., 2011). 
However, MIC determinations revealed that both strains were more susceptible to Pep5 
(Table 11). Additionally, the LTA-deficient suppressor strain ∆ltaS (4S5) showed a 
decreased MIC value against RTDs compared to its parental strain (Table 11). As LTA are 
crucial for bacterial growth, the strain ∆ltaS (4S5) compensates the loss of LTA by 
increasing the intracellular level of the secondary messenger c-di-AMP. It has been 
suggested that this messenger plays a role in cell division, but it has to be further 
elucidated whether c-di-AMP is involved in the regulation of other cellular processes.  
S. aureus SEJ ∆ltaS (4S5) is also more susceptible to cell wall inhibitors such as nisin, 
vancomycin and penicillin as well as to daptomycin (Corrigan et al., 2011). Thus, the 
decreased MIC values of Pep5 and RTDs might be a secondary effect due to yet 
unknown altered cellular processes in this strain. Alternatively, it can be hypothesised that 
in case of a reduced LTA content, peptides more easily directly interfere with the bacterial 
membrane, thereby leading to membrane permeabilisation even in the absence of a high 
membrane potential.  
In the strain S. aureus SA113 ∆ypfP the remaining LTA is anchored to the membrane via 
diacylglycerol (DAG) instead of diglucosyl-DAG. In this case, the binding of Pep5 to LTA 
could still have an impact on the membrane integrity as binding sites are even closer to 
the outside of the cytoplasmic membrane.  
Interestingly, S. simulans and S. carnosus are more susceptible towards Pep5 (Sahl and 
Brandis, 1981) and θ-defensins than S. aureus (Table 10, Table 11). The LTA in these 
strains does not differ and consists of a polyglycerolphosphate chain linked to a glycolipid 
anchor (Ruhland and Fiedler, 1990). However, modifications of the LTA such as 
substitution of the glycerol units with D-alanine may have an impact on the susceptibility 
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as it adds a positive charge to the polyanionic molecules. Brötz et al. (1998) suggested 
that the Pep5 docking molecule might be more prominent or better accessible in these 
strains. Recently, a phylogenetic study of Atl proteins derived from 15 staphylococcal 
species revealed that the second repeat of the Atl-AM from S. simulans and S. carnosus 
completely differs from those of all other species (Albrecht et al., 2012). As Atl proteins 
target glycerophosphate-containing LTA via their repeats (Zoll et al., 2012), the sequence 
of the repeat unit might influence the binding to LTA. Thus, the enzymes might be easier 
released by cationic peptides such as RTDs and Pep5 in these species. 
All the results described above indicate that Pep5 and RTDs may have a similar mode of 
action against staphylococci. This was further substantiated by the fact that the 
heterologous expression of PepI – which is secreted by the Pep5 producer strain to 
protect itself – provided partially cross-resistance towards RTDs (Table 13). However, this 
raises questions about the interaction partner for PepI. One could hypothesise that PepI 
forms a complex with LTA, thereby inhibiting the binding of the antimicrobial peptides and 
subsequently the displacement of the autolytic enzymes. Nevertheless, this interaction 
would probably also interfere with the targeting and the activity of Atl.  
 
 
 
Figure 28 Proposed mode of action of θ-defensins. The peptides disrupt the membrane barrier 
function in presence of a high membrane potential (∆Ψ) by a yet unknown mechanism. 
Moreover, RTDs release autolytic enzymes (marked in orange) by interaction with LTA, 
thereby causing uncontrolled degradation of the cell wall. 
 
In addition, RTDs exhibit activity against Gram-negative bacteria in a similar concentration 
range as against Gram-positives (Tang et al., 1999; Tran et al., 2008; Tran et al., 2002). 
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Tran et al. (2008) reported that RTD-1 and RTD-2 effectively permeabilise the outer and 
inner membrane of E. coli ML35-pYC, whereas RTD-3 (Figure 12) does not affect the 
membrane. This membrane impairment seems to be independent from the membrane 
potential as these assays were carried out in buffer lacking free glucose. 
Further studies are necessary to analyse if RTDs additionally interfere with membrane 
bound molecules in Gram-negative bacteria.  
4.3 Part 3: Interaction of hBD3 with the Gram-negative cell envelope 
The antibacterial activity of the highly cationic peptide hBD3 was extensively studied in  
S. aureus and it has been demonstrated that binding to lipid II and subsequent inhibition 
of cell wall biosynthesis is a major determinant of its mechanism of action (Sass et al., 
2008; Sass et al., 2010). Here, the interaction of hBD3 with the cell envelope of E. coli 
was investigated to gain a first insight into its antibiotic action against Gram-negative 
bacteria.  
Initially, the defensin has to cross the outer membrane barrier of Gram-negative bacteria 
to gain access to the periplasmic space. This may occur by a mechanism known as self-
promoted uptake which is based on the interaction of the cationic peptides with the 
negatively charged LPS molecules of the outer membrane (compare 1.3) (Hancock, 
1997). In fact, hBD3 rapidly disrupted the outer membrane of E. coli ML35-pYC 
comparable to the membranolytic activity of polymyxin B (Figure 24). Consistently, 
evaginations of the outer membrane could be observed by transmission electron 
microscopy (Figure 25) which are indicative of LPS released from the cell surface 
(Spindler et al., 2011).  
To further analyse the interaction of hBD3 with LPS, the susceptibility of strains with 
altered LPS structure was tested (Figure 26). LPS molecules typically consist of three 
distinct regions: a hydrophobic membrane anchor (lipid A), a short sugar chain substituted 
with phosphate groups (core) and a polymer composed of oligosaccharide repeats (O 
antigen). Interestingly, all three mutants of the E. coli K-12 strain BW25113 (∆waaP, 
∆waaY, ∆waaG) included in the study were more resistant towards hBD3. These mutants 
are affected in the assembly of the LPS core region. The WaaP and WaaY kinases are 
involved in the phosphorylation of the first and second heptose residue in the inner core 
(Yethon et al., 1998). Thus, a deletion of one of the genes reduces the net negative 
charge of the cell envelope which correlates with a decreased susceptibility towards 
cationic peptides, as observed here. On the other hand, the phosphoryl substituents are 
critical for the formation of a stable outer core, because their negative charge allows 
neighbouring LPS molecules to be crossbridged by divalent cations (Helander et al., 1989; 
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Yethon et al., 2000). It has been shown that waaP deletion mutants are highly susceptible 
towards polymyxin B or detergents such as SDS (Yethon et al., 2000; Yethon et al., 
1998). Nevertheless, among the tested strains E. coli ∆waaP displayed the highest 
resistance.  
The gene waaG encodes a glycosyltransferase which adds the first glucose to the outer 
core; consequently the deletion strain lacks the entire outer core region. These results 
suggest that not only the phosphate groups, but also the sugars of the outer core region 
may be crucial for the interaction with hBD3 whereas the O antigen does not seem to be 
involved in binding (Figure 26). 
Further, the question is raised whether outer membrane permeabilisation is sufficient by 
itself to cause bacterial cell death or if additional target structures are involved in hBD3-
mediated killing of Gram-negative bacteria. 
It could be hypothesised that hBD3 interacts with the cell wall precursor lipid II once it 
enters the periplasmic space. Studies with chimeric and shortened hBD3 molecules linked 
the Gram-positive activity to the N-terminal part and the action against Gram-negative 
bacteria to the C-terminus (Hoover et al., 2003; Jung et al., 2011). This suggests that the 
highly charged C-terminal part of hBD3 (compare Figure 22) is essential for its interaction 
with the outer membrane, whereas the N-terminal part plays a predominant role in the 
interaction with lipid II. Moreover, hBD3 forms stable dimers in solution (due to an 
intermolecular salt bridge between E28 and K32 on another monomer) supporting the 
interaction with the membrane. Additionally, an intramolecular salt bridge involving the 
residues E27 and R17 (Schibli et al., 2002) contributes to stability and enhances the 
membrane-disrupting properties of hBD3 (Boniotto et al., 2003).  
Consequently, hBD3 combines two activities in one molecule in contrast to oyster 
defensins which have only a weak membrane-disrupting activity and are barely active 
against Gram-negative bacteria. This correlates with the affinity to the cell wall precursor 
lipid II as discussed before (compare section 4.1). 
However, growth kinetic measurements indicated that the mode of action of hBD3 against 
Gram-negative bacteria is different from the action against S. aureus (Figure 23) and that 
other target structures might also be involved in killing. Sass et al. (2010) demonstrated 
that the activity of hBD3 can be antagonised by the lipid II isoprenoid anchor C55-P in a 
molar ratio of 2:1. This lipid carrier is also involved in the biosynthesis and modification of 
LPS, suggesting that hBD3 might also interfere with these processes. For example, the 
repeating units of the O antigen are assembled on C55-P on the inner face of the 
cytoplasmic membrane. After transport across the membrane, the O antigen is 
polymerised and ligated to lipid A-core (Raetz and Whitfield, 2002; Wang and Quinn, 
2010).  
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Further, the inner membrane was permeabilised to some degree by hBD3, but less 
efficiently as with polymyxin B (Figure 24), indicating a higher affinity of hBD3 to the outer 
membrane. Nevertheless, this interaction did not cause a significant loss of cytoplasmic 
content as monitored by transmission electron microscopy (Figure 25) and growth kinetic 
measurements (Figure 23). A similar lack of lytic effects has been reported for the 
synthetic antimicrobial peptide Bac8. This peptide was shown to cause partial membrane 
permeabilisation, disruption of the electron transport chain located in the inner membrane 
and cell depolarisation which in turn results in cell death (Spindler et al., 2011). 
Consistently, microarray data of hBD3 treated S. aureus cells indicated that energy 
generation is affected in presence of the peptide (Sass et al., 2008). This suggests that 
hBD3 might also inhibit cellular respiration by either direct or indirect disruption of 
respiratory functions.  
In conclusion, binding to LPS and subsequent destabilisation of the cell envelope seems 
to play a significant role in the mode of action of hBD3 against Gram-negative bacteria 
and may be more important than the interaction with lipid II. Moreover, it is likely that 
hBD3 interferes with various membrane-bound processes in E. coli which may each 
contribute to the overall efficacy. Since the defensin causes stresses at many sites, it may 
act like “sand in the gearbox” – a mechanism which has been described for α-helical 
HDPs (Pag et al., 2008). 
However, further studies are necessary to investigate the inhibition of these individual 
processes in more detail and to correlate them with the loss of cell viability (section 4.5).  
4.4 Conclusion 
Altogether, defensins of different groups interact with molecules of the microbial cell 
envelope that are directly accessible such as lipid II, LTA or LPS (Table 15). Thereby, the 
interaction between the defensin and the lipid-bound docking molecule can be highly 
specific as shown for lipid II and antibacterial CSαβ-type defensins.  
Interestingly, similarities in the mode of action between some eukaryotic defensins and 
bacterially-produced lantibiotics could be revealed. The lantibiotic nisin and antibacterial 
invertebrate and fungal defensins bind to the pyrophosphate moiety of the highly 
conserved cell wall precursor lipid II. Moreover, Pep5 and θ-defensins do not only disrupt 
the membranes barrier function, but they also release the major autolysin Atl in 
staphylococci probably by replacing the enzymes from LTA.  
Despite their low sequence similarity, these cationic peptides share many features as 
amphipathicity and cationicity. Moreover, their structures are stabilised by disulphide 
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bridges or (methyl)lanthionines, respectively. Thus, the antimicrobial activity may depend 
on the overall conformation and charge distribution rather than on their primary sequence.  
Since some defensins inhibit specific microbial targets without impacting membranes, they 
are considered attractive candidates for further development as anti-infective drugs. For 
instance, NZ2114 – an improved variant of the fungal defensin plectasin – showed potent 
activity in rodent infection models against clinically relevant strains such as MRSA and 
VRE, enhanced serum-stability, and extended in vivo half-life (Andes et al., 2009; Xiong et 
al., 2011).  
 
Table 15 Known target structures of various defensin groups. 
Defensin group Example Target structure Reference 
antibacterial  
CSαβ-type defensins 
plectasin 
Cg-Defs 
lipid II  
(high affinity) 
Schneider et al., 2010 
this study 
antifungal  
CSαβ-type defensins 
heliomicin 
Rs-AFP2 
GlcCer Thevissen et al., 2004 
Aerts et al., 2009 
α-defensins HNP-1 lipid II  
(intermediate affinity) 
de Leeuw et al., 2010 
β-defensins hBD3 lipid II  
(intermediate affinity) 
LPS 
Sass et al., 2010 
 
this study 
θ-defensins RTDs LTA 
cytoplasmic membrane 
this study 
 
4.5 Outlook 
In this study, the antistaphylococcal activity of two θ-defensins was investigated. It was 
shown that these peptides do not only impair the membrane barrier function, but also 
liberate the staphylococcal autolysin Atl from LTA in a similar way as the lantibiotic Pep5. 
However, several open questions remain to be further investigated. For example, MIC 
determinations revealed that the strains S. aureus SA113 ∆ypf and S. aureus SEJ ∆ltaS 
(4S5) – which are characterised by a reduced LTA content – were more sensitive towards 
Pep5 and in part to RTDs. In this context, it was reasoned that in absence of LTA the 
peptides can more easily interfere directly with the bacterial membrane. To confirm this 
hypothesis, the peptide-induced membrane perturbation of the mutants could be tested in 
comparison to the parental strain, e.g. by membrane potential measurements.  
Moreover, it would be interesting to monitor the binding of the peptides to the bacterial cell 
envelope and the subsequent release of the enzymes using fluorescence microscopy. Zoll 
et al. (2012) demonstrated that externally applied Cy5-labelled repeats of the Atl-AM 
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accumulate at the cross wall of dividing S. aureus cells. Thus, it would be expected that 
treatment with RTDs causes a delocalisation of the repeats from the septum.  
Further, it was shown that the heterologous expression of the immunity peptide PepI of 
the Pep5 producer strain provided partially cross-resistance towards RTDs. Nevertheless, 
further studies are necessary to gain a deeper insight into the mechanism by which the 
molecule confers resistance. Hoffmann et al. (2004) reported that PepI localises in the 
outer leaflet of the cytoplasmic membrane and that the highly charged C-terminal part is 
crucial for antagonising Pep5 activity. However, it is still unknown whether PepI forms a 
complex with lipid-bound molecules of the staphylococcal cell envelope or whether it 
interacts directly with the cationic peptides Pep5 or RTDs, thereby preventing interference 
with both the bacterial membrane and LTA. The fact that the C-terminus of PepI 
possesses several positively charged amino acids rather suggests that it forms a complex 
with anionic molecules such as LTA. Thus, it could be first investigated whether PepI can 
antagonise both activities of the peptides. The potassium efflux of energised cells 
expressing PepI under an IPTG-inducible promotor could be monitored to test whether 
PepI can inhibit the peptide-induced membrane permeabilisation (compare section 2.3.8). 
In additon, the supernatant of peptide treated cells expressing PepI could be analysed for 
cell wall lytic activity in comparison to control cells (compare section 2.5.3).  
 
In the third part of this thesis, the interaction of hBD3 with the cell envelope of E. coli was 
investigated. It was demonstrated that the peptide permeabilise the outer membrane by 
binding to LPS and that the composition of the LPS core region plays an important role in 
this interaction. To gain a deeper insight into the interaction of LPS and hBD3, binding 
analysis using surface plasmon resonance could be carried out. Further, killing kinetics of 
hBD3 treated E. coli cells might correlate the permeabilisation of both membranes with the 
loss of cell viability. 
Moreover, some interference of hBD3 with the inner membrane could be detected. In this 
context, it would be interesting to measure the depolarisation of the membrane in 
presence of hBD3 (compare section 2.3.9). Further, it has been suggested that hBD3 
affects directly or indirectly the electron transport chain located in the inner membrane. To 
analyse the effect of hBD3 on respiration, the intracellular NAD+/NADH ratios or the 
oxygen consumption of cells exposed to hBD3 should be measured. Specific inhibition of 
the individual electron transport chain complexes could be studied in vitro using inverted 
membrane vesicles.  
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5 Summary 
Multicellular organisms defend themselves against infectious microorganisms by 
producing a wide array of antimicrobial peptides referred to as host defence peptides 
(HDPs). These evolutionary ancient peptides are important effector molecules of innate 
immunity. In addition to their immunomodulatory functions, they display potent direct 
antimicrobial activity against a broad range of microorganisms, including multiresistant 
pathogens. Thus, they are considered as promising candidates for the development of 
novel anti-infective agents.  
Almost all HDPs are cationic and amphipathic. Hence, it has been generally assumed that 
these peptides interact unspecifically with negatively charged microbial membranes and 
subsequently disrupt membrane barrier functions. However, evidence is increasing that 
the antibiotic activity of HDPs can be much more targeted as it was originally proposed. 
One important HDP class comprises defensins which are characterised by disulphide-
stabilised β-sheets as the major structural component. In this work, the mode of action of 
defensins from diverse origins was investigated to gain further insights into the molecular 
mechanisms of defensin-mediated killing.  
 
In the first part of this work, the antibacterial action of invertebrate defensins was studied 
using three defensin variants (Cg-Defm, Cg-Defh1 and Cg-Defh2) produced by the Pacific 
oyster Crassostrea gigas. These peptides exhibited potent activity against several Gram-
positive bacteria, including staphylococci which were chosen for further mode of action 
studies. Interestingly, the oyster defensins did not compromise the membrane integrity 
since no impact on the membrane potential could be observed in cells exposed to these 
peptides. Instead, the defensins triggered the accumulation of the final soluble cell wall 
precursor UDP-MurNAc-pp in the cytoplasm, comparable to classical inhibitors of the 
membrane-bound steps of cell wall biosynthesis. Moreover, the oyster defensins were 
found to bind irreversibly to the cell wall precursor lipid II in a 1:1 stoichiometry, thereby 
causing sequestration of the precursor from penicillin binding proteins and subsequently 
blocking its further incorporation into the cell wall. Among the oyster defensins, Cg-Defh2 
was the most potent, exhibiting 2- to 4-fold lower MIC values than Cg-Defh1 and Cg-
Defh2, which correlated with different binding affinities for lipid II as revealed by surface 
plasmon resonance.  
 
The second part of this thesis was aimed at elucidating the antistaphylococcal action of 
two rhesus macaque θ-defensins (RTD-1, RTD-2). These peptides differ structurally from 
all other defensins in that their backbones are cyclised by peptide bonds. Potassium efflux 
experiments and membrane potential measurements demonstrated that the membrane 
impairment by RTDs strongly depends on the energisation of the membrane. In addition, 
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RTD treatment caused the release of the cell wall lytic enzyme Atl probably by interaction 
with the membrane-bound lipoteichoic acid. Thus, the premature and uncontrolled activity 
of this enzyme contributes strongly to the overall killing by θ-defensins. Interestingly, a 
similar mode of action has been described for Pep5, an antimicrobial peptide of bacterial 
origin. Consistently, PepI – which is secreted by the Pep5 producer strain to protect itself 
– provided partially cross-resistance towards RTDs.  
 
In the third part of this thesis, the antimicrobial activity of the human β-defensin 3 (hBD3) 
against Gram-negative bacteria was studied. Previous works have reported that binding to 
lipid II and subsequent inhibition of cell wall biosynthesis is a major determinant of its 
mechanism of action against staphylococci. 
Here, it was demonstrated that the peptide permeabilises both the inner and outer 
membrane of E. coli. The interaction of the peptide with the lipopolysaccharides (LPS) of 
the outer membrane seems to play a significant role in the activity of hBD3 against Gram-
negative bacteria and was shown to depend on the number of phosphate groups and the 
sugars in the LPS core region. Interestingly, the interaction with the inner membrane did 
not cause a significant loss of the cytoplasmic content as revealed by growth kinetic 
measurements and transmission electron microscopy of hBD3 treated E. coli cells. It 
remains to determine if additional target structures in the inner membrane such as the 
electron transport chain are also involved in hBD3-mediated killing. 
 
In conclusion, previous reports and the results described in this thesis revealed that 
conserved molecules of the microbial cell envelope, which are readily accessible, are 
targets of various defensins and an important component of the killing mechanism. As 
demonstrated here for lipid II and oyster defensins, the interaction between the defensin 
and its lipid-bound target molecule can be highly specific. 
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